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hronic obstructive pulmonary disease (COPD) is an insidiously 
debilitating disease with a progressive nature that is commonly 
treated in primary care. It is characterized by airflow obstruction 
that is not fully reversible.1 Most COPD patients experience mild-to-
moderate airflow obstruction.2 Still, high levels of dyspnoea and reduced 
health related quality of life are prevalent in this population.3,4 
 
In addition to symptoms resulting from COPD, patients also frequently 
suffer from comorbid conditions such as congestive heart failure and 
diabetes mellitus.5 Comorbid conditions could affect health status and 
treatment options, and therefore, be important to identify. 
The focus of COPD management in primary care is on alleviation of 
respiratory symptoms, smoking cessation, improvement of exercise 
capacity, and prevention and early treatment of exacerbations.1,6 To guide 
COPD management, general practitioners (GPs) and practice nurses 
periodically collect information on a patient’s disease state, or ‚monitor‛ 
patients.7 The skills required for COPD monitoring include knowledge of 
the execution of spirometric tests, interpretation of test results, as well as 
keeping abreast of the latest in COPD disease management. Regional 
primary care diagnostic centres in the Netherlands offer monitoring 
services for patients with COPD. These centres provide regular testing of 
markers of disease and the parameters of treatment, and provide 
recommendations for GPs to consider in their treatment of patients.  
 
The value of monitoring remains somewhat dubious; there is no evidence 
that monitoring influences the quality of care and outcome of COPD. 
Moreover, the clinical effectiveness of the monitoring services by diagnostic 
centers that are already fully operational has not been proven. The 
dissertation focuses on monitoring disease, treatment, and comorbidity of 
primary care COPD patients. 
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COPD DEFINITION AND MANAGEMENT  
COPD is “a disease state characterized by airflow limitation that is not fully 
reversible. The airflow limitation is usually both progressive and associated with an 
abnormal inflammatory response of the lungs to noxious particles or gases.”1 In 
the Netherlands, the prevalence of COPD is higher in males than in females 
(respectively 2.2% and 1.7% of the total adult population in 2003), and 
increases with age.8 Cigarette smoking is the primary risk factor of COPD 
in developed countries.9 Currently, 28 percent of the Dutch population 
smoke cigarettes.10 
 
Common COPD symptoms include sputum production, coughing, 
wheezing, and dyspnoea. Acute exacerbations can occur during the course 
of COPD and are heralded by increased symptom severity. As COPD 
progresses, exacerbations become more prevalent. Exacerbations negatively 
impact patients’ quality of life and further deteriorate lung function.11,12 In 
2004, 4.1% of overall mortality in the Netherlands was related to COPD, 
and therefore, COPD has one of the highest mortality rates of those with 
chronic diseases.8   
 
COPD is diagnosed by spirometry. If the forced expiratory volume in one 
second (FEV1) is less than 70 percent of the total forced vital capacity (FVC) 
(i.e., FEV1/FVC < 0.7), the patient falls within the COPD classification.1,13 The 
severity of COPD is usually based on the level of airflow limitation 
expressed as a percentage of the predicted FEV1.1 Based on the level of 
airflow limitation, the majority of patients (82%) is classified as having 
mild-to-moderate COPD.2  
 
However, the traditional viewpoint that COPD is a disease of chronic 
airflow obstruction alone has advanced to a model that considers COPD to 
be a multicomponent disease that involves extrapulmonary effects like 
decreased exercise capacity and muscle depletion.  
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It is still an question whether these non-pulmonary sequelae of COPD 
frequently occur in patients in the primary care setting, since there is 
generally a predominance of mild cases in this population.2 An good 
example is the energy disbalance in COPD patients. It seems likely that the 
energy balance will be more off-balanced when the disease progresses into 
its more severe stages. The energy requirement will increase when disease 
progresses, while the appetite and physical energy to eat decrease when 
dyspnoea increase. So, it is still an open question if energy (off) balance is a 
predominant problem in patients with mild-to-moderate COPD.  
 
In general, the goals for the management of COPD are to delay disease 
progression and alleviate its manifestations. To be more precise, the 
management of COPD aims to1 : a) prevent disease progression; b) relieve 
symptoms; c) improve exercise tolerance; d) improve health status; e) 
prevent and treat complications; f) prevent and treat exacerbations; and g) 
reduce mortality.  
 
Regular follow-up visits of patients with COPD, also called monitoring, 
may facilitate optimal patient care, by providing insight into the disease 
state or progression that is responsive to change.7 The periodic collection of 
information can be done by the GPs themselves, by practice nurses or by 
external organisations.  
 
Many guidelines on the management of COPD recommend such regular 
follow-up visits, but differences exist between the recommendations in 
these guidelines. Recently, an international collaboration of stakeholders in 
COPD management held a workshop to develop a vision statement for new 
respiratory diseases guidelines.14  
 
The statement calls for the use of global COPD knowledge, focus on issues 
important to both patients and clinicians, and cooperation of all relevant 
parties to develop a universal guideline on COPD. An overview of current 
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monitoring recommendations of COPD guidelines and evidence to support 
these recommendation could help globalising knowledge on one of the 
important issues in managing COPD.  
 
COMORBIDITY IN PATIENTS WITH COPD 
Patients with chronic airway obstruction (COPD and asthma) are more 
likely to have other medical conditions like cardiovascular diseases, 
diabetes mellitus, osteoporosis, locomotive diseases, insomnia, sinusitis, 
migraines, and cancer.5 The coexistence of COPD and other medical 
conditions, or comorbidity, can be explained by numerous factors. Some of 
these conditions (for instance, lung cancer) share a common risk factor: 
cigarette smoking. Further, cigarette smoking and other life-style risk 
factors (e.g., lack of physical activities and malnutrition) frequently co-
occur,15 increasing the risk for medical conditions like diabetes mellitus. 
Also, pathophysiological links exist between COPD and some of the other 
comorbid conditions, such as congestive heart failure. Finally, patients with 
COPD are usually aged, and as multimorbidity is common in older 
individuals, it is also common in COPD patients.16,17 
 
Depression is frequently linked to COPD. The putatively high risk for 
depression of COPD patients is alarming, since depression can further 
deteriorate the health status of COPD patients.18 A considerable amount of 
literature has been published on depression rates in COPD,19-26 though 
these studies may be compromised by their tendency to rely on 
questionnaires that include symptoms of COPD, like fatigue and 
sleeplessness, overstating ‚depression‛ scores. In addition, evidence of the 
relation between COPD and depression is based on cross-sectional studies 
and, consequently, do not include crucial information on the temporal 
relation between COPD and depression. 
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Last, while little is known about the prevalence of obesity in COPD patients 
and the consequences of this comorbid condition for dyspnoea levels and 
lung function in patients with COPD, it can be assumed that carrying 
excessive body fat is disadvantageous, particularly for patients with 
dyspnoea.  
 
Comorbidity has serious implications for disease management. GPs have to 
be aware that some treatments may be sensitive to confounding or 
deleterious effects in patients with comorbidity. For instance, beta-blockers 
used to treat cardiac disease or glaucoma may increase bronchoconstriction 
in patients with COPD.  For patients, comorbidity could negatively impacts 
their quality of life.  From a societal perspective, comorbidity increases 
hospital admissions and health care costs.27-29 With timely and appropriate 
action, some of the comorbid conditions may be prevented, alleviated, or 
treated more effectively. 
 
THE ROLE OF PRIMARY CARE DIAGNOSTIC CENTRES WITHIN 
THE DUTCH HEALTH CARE SYSTEM  
Within the Dutch health care system, primary care professionals provide 
health care for patients listed with their practice and operate as 
‚gatekeepers‛ for specialized secondary care. Roughly 96 per cent of all 
episodes of illness presented to the GP are fully treated in primary care.30 
Many GPs and practice nurses rely on regional diagnostic centers (RDCs) 
to facilitate diagnostic procedures (e.g., ECGs, blood tests, and magnetic 
resonance imaging to measure bone density) and monitor patients for 
COPD among other chronic diseases (e.g., congestive heart failure, diabetes 
mellitus, and asthma). Thus, RDCs offer primary care professionals the 
opportunity to diagnose and manage patients without direct involvement 
of medical specialists. 
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RESPIRATORY EXPERT SUPPORTED MONITORING SYSTEM FOR 
PRIMARY CARE 
The way regional diagnostic centers facilitate monitoring COPD for 
primary care can be illustrated with an overview of the procedures of the 
‚Stichting Huisartsen Laboratorium (SHL).” SHL is a pioneering regional 
diagnostic centre located in the southern part of the Netherlands that has 
monitored patients with asthma or COPD since 1995. Similar programs are 
or have now been implemented in other areas in the Netherlands, such as 
in the Eindhoven region, Maastricht region, Arnhem region, and northeast 
Groningen region. Approximately 7,000 patients with asthma or COPD are 
diagnosed or monitored by SHL on a yearly basis according to current 
figures.  Figure 1 visualizes the monitoring system. 
 
Figure 1. Schematic overview of the respiratory expert supported monitoring system of 
patients with asthma or COPD as provided by primary care diagnostic centers. 
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According to this monitoring system, patients with asthma or COPD are 
invited for monitoring visits every year by the SHL (Step A). Airflow 
obstruction is measured with a spirometer (SpiroPerfect®, WelchAllyn, 
Delft, The Netherlands) by certified lung function technicians. Information 
on body mass index (BMI), respiratory symptoms, exacerbations, smoking, 
and medication use in the previous year is collected. Next, a respiratory 
expert (either a chest physician or a GP with a special respiratory focus) 
evaluates the information from the monitoring visit and previous visits 
(Step B). The respiratory expert then formulates recommendations on 
pharmacological and non-pharmacological treatment, additional diagnostic 
tests, and referrals to other disciplines, based on national clinical practice 
guidelines for COPD and asthma.31,32 The expert’s interpretation based on 
spirometry results and written information only (without an actual office 
visit by the patient) has been shown to be valid.33 Next, written feedback is 
send to the patient’s GP. The patient is instructed to visit the GP’s surgery 
within two weeks, to discuss the outcome of the monitoring visit (Step C). 
This allows the GP to consider the expert recommendations (Step D). A 
nurse consultant conducts outreach visits to assist in the implementation of 
the recommendations (Step E). 
 
Even though it is widely implemented, the clinical effectiveness of these 
monitoring programs has never been established. The only data available 
are process evaluations of a few comparable COPD asthma monitoring 
models. The inherent limitation of the process evaluations is that they 
solely describe the process without linking the process to its clinical 
effectiveness. Initial results from a comparable COPD asthma monitoring 
model indicates that a higher percentage of practitioners issued smoking 
cessation, with a ‚self reported‛ decrease in smokers in the monitored 
group of more than 10%.34 
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The percentage of patients in the monitored group that used their inhaler 
correctly also increased. In another study, no additional effect other than 
patient satisfaction was reported from providing feedback to the GP on 
patients’ smoking habits, lung function, and use of medication compared to 
usual care.35 
 
The inconclusive results supporting the value of monitoring disease state 
and disease progress in patients with COPD in primary care, as well as the 
lack of information on some monitoring factors and comorbid conditions, 
form the basis for the following research questions in this thesis: 
1. What are current COPD guidelines on monitoring routines, 
recommended frequency of monitoring visits, and level of scientific 
evidence supporting these recommendations? 
2. What is the prevalence of three prognostic monitoring factors (i.e., 
(1) low Body Mass Index (BMI), (2) moderate or severe dyspnoea, 
and (3) moderate or severe airflow obstruction) in a primary care 
COPD population and what is the concurrent occurrence of these 
factors in COPD patients?  
3. What is the incidence of depression in patients with COPD and is 
the risk for depression higher in COPD patients compared to 
patients with another chronic disease (i.e., diabetes mellitus) as well 
as compared to individuals without chronic conditions? 
4. What is the prevalence of obesity in COPD patients and does 
obesity result in worse lung function and more respiratory 
symptoms than in a combined population of normal weight and 
overweight patients?  
5. What is the long-term effectiveness of a primary care monitoring 
system with respiratory expert recommendations for primary care 
management of COPD patients as compared to usual care?  
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OUTLINE OF THE DISSERTATION 
Chapter 1 discusses the rationale for monitoring patients with COPD. 
Chapter 2 summarizes the monitoring recommendations according to 
clinical practice guidelines. Chapter 3 presents the prevalence of prognostic 
monitoring factors and their co-occurrence in a primary care COPD 
population. Chapter 4 describes the results of a prospective, dynamic, 
cohort study on the risk of doctor-diagnosed depression in patients with 
COPD as compared to patients with diabetes and ‚healthy‛ controls, 
followed by the prevalence and consequences of obesity in patients with 
COPD in primary care in Chapter 5. Finally, Chapter 6 analyses the results of 
a respiratory expert supported monitoring system for primary care COPD 
patients. In this chapter special attention is paid to the evaluation of the 
process of monitoring to determine the utility of the intervention. The 
discussion chapter includes implication of the findings to future research 
into this area and daily primary care. The last chapter summarizes the 
dissertation.  
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he Global initiative for chronic Obstructive Lung Disease (GOLD) 
guideline serves as an international reference for evidence-based 
management of patients with chronic obstructive pulmonary 
disease (COPD).1 Based on the available scientific evidence, 
recommendations for diagnosis and treatment are presented. An important 
goal of the GOLD initiative is to counter the nihilistic attitude and to 
promote a proactive engagement of physicians and allied healthcare 
professionals with COPD patients over time.2 In addition, GOLD, and also 
other guidelines, recommend regular surveillance of patients’ respiratory 
health status.1,3-19 The rationale behind the regular follow-up of patients 
with chronic conditions, also referred to as ‚monitoring‛, is that it 
facilitates optimal outcome of patient care.20,21  
 
However, care of COPD implicates large numbers of patients and, 
consequently, monitoring their health status would result in substantial use 
of healthcare resources. In the present paper, the authors reflect on 
monitoring, as currently recommended in COPD guidelines, and discuss 
the rationale behind it, including some pros and cons of the procedures 
involved. 
 
A total of 18 clinical guidelines published or updated after the year 2000 
that address the diagnosis, treatment and (end-of-life) care of COPD were 
analysed (Table 1.1).1,3-19  
T 
  
Table 1.1.  Clinical practice guidelines for chronic obstructive pulmonary disease. 
Abbreviations Organisation Year# Country / region 
Evidence grading 
of monitoring  
recommendations 
Separate paragraph 
on monitoring/ 
follow-up     
GOLD¶ Collaboration of many organisations including 
American Thoracic Society, European Respiratory 
Society and WHO 
2006 Global No Yes 
ATS/ERS American Thoracic Society and European 
Respiratory Society 
2004 Global NA§ Yes 
IPAG§ International Primary Care Airway Group 2004 Global NA Yes 
IPCRG¶,+ International Primary Care Respiratory Group 2006 Global Yes Yes 
EBM¶ Duodecim medical publications Ltd 2004 Global No No 
COPD-X¶ Thorax Society for Australia and New Zealand 
and the Australian Lung Foundation 
2006 Australia/ 
New Zealand 
No Yes 
CTS¶ Canadian Thoracic Society 2004 Canada No No 
BCMA British Columbia Medical Association 2005 Canada NA No 
India WHO (India) 2003 India NA No 
CBO¶ Collaboration of many organisations including 
Dutch College of General Practitioners and Dutch 
Institute for Health Care 
2005 The Netherlands Yes Yes 
NHG Dutch College of General Practitioners 2001 The Netherlands NA Yes 
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Table 1.1. continued  
Abbreviations Organisation Year# Country / region 
Evidence grading 
of monitoring  
recommendations 
Separate paragraph 
on monitoring/ 
follow-up 
PA Palestinian Ministry of Health 2003 Palestinian 
region 
NA Yes 
SA South African Thoracic Society 2004 South Africa NA No 
SRS¶ Swiss Respiratory Society 2002 Switzerland No No 
Prodigy¶ National Health Service and Department of 
Health UK 
2006 UK No Yes 
NICE¶ National Collaborating Centre for Chronic 
Conditions. 
2004 UK Yes Yes 
ISCI¶ Institute for Clinical System Improvement USA 2005 USA No Yes 
ABFP American Board of Family Practice 2001 USA NA Yes 
GOLD: Global Initiative for Chronic Obstructive Lung Disease, WHO: World Health Organization, EBM: Evidence-Based Medicine Guidelines, CBO: Dutch Institute for Healthcare 
Improvement, NA: not applicable, #: year of initial publication or, in the case of periodic revision of the guideline, the year of the most recent update; ¶: evidence grading for at least 
one recommendation in the guideline; +: guidelines developed by the same group of experts; §: not applicable since the guideline did not use systematic evidence grading. 
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All but one of these guidelines19 recommend regular monitoring, in 
particular of lung function, but also of respiratory symptoms, smoking 
habits, nutritional status, exercise tolerance and presence or progression of 
comorbid conditions (Table 1.2).1,3-18 However, none of the guidelines 
provided evidence for the recommended monitoring. This is not really 
surprising, as there is a complete lack of empirical studies that have 
addressed this particular issue. Consequently, recommended monitoring is 
almost exclusively expert opinion-based and, given the potential impact on 
costs and resources, this warrants at least some discussion. 
 
In a number of cases the advice to monitor is self-evident, e.g., for smoking 
cessation, where individually tailored advice and support require up-to-
date information on current smoking status. However, this is not the case 
for the monitoring of lung function, the most often recommended 
monitoring routine for patients with COPD. Lung function testing is 
essential for the diagnosis of COPD and to stage its severity,22 but the 
progressive decline of lung function is resistant to treatment other than 
smoking cessation.23 As a consequence, there is little value in monitoring a 
patient’s lung function decline once the diagnosis has been made. 
However, as the disease progresses, periodic reassessment of the severity 
of airflow obstruction enables periodic restaging and concomitant stage-
specific treatment recommendations. An example is treatment with inhaled 
steroids to prevent exacerbations, which is only recommended for patients 
with a forced expiratory volume in one second, 50% of the predicted 
value.1,24 
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Table 1.2.The most frequently recommended monitoring routines in clinical practice 
guidelines for chronic obstructive pulmonary disease. 
Monitoring routines Guidelines mentioning monitoring routine 
(n = 18) 
Lung function 15 ( 83) 
Symptoms / dyspnoea  14 ( 78) 
Smoking habits 12 ( 67) 
Exercise tolerance 10 ( 56) 
Comorbidity / complications 10 ( 56) 
Exacerbations   9 ( 50) 
Inhaler technique   8 ( 44) 
Side effects of treatment     8 ( 44) 
Effect of drug treatment    7 ( 39) 
Nutritional condition   7 ( 39) 
Compliance with treatment   7 ( 39) 
Data are presented as n (%), unless otherwise stated. Only routines that are recommended in seven or more of the 
guidelines are shown. 
 
Since the majority of patients with COPD suffer from mild-to-moderate 
disease25 and progression to a more severe disease stage will often take 
several years, the cost of monitoring lung function in all patients should be 
offset against its limited yield. Monitoring of nutritional status can be 
looked at in a similar way: based on current knowledge, monitoring of 
nutritional status provides information on prognosis in patients with 
severe-to-very severe COPD,26,27 but for patients with mild-to-moderate 
disease the prognostic value of poor nutritional status has not been 
established. As long as there is no sound evidence that patient outcomes or 
prognosis can be improved by nutritional intervention, there is no clear 
purpose for collecting information on nutritional status in patients with 
mild-to-moderate disease.28,29 
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From this, it can be inferred that monitoring in COPD may serve different 
goals: grading the severity of the disease;1,26 selecting applicable treatment 
options, i.e., inhaled corticosteroids24 or oxygen therapy;1 or predicting the 
prognosis of the disease. These goals should be reflected in the application 
of monitoring routines: while assessment of symptoms and initiated 
treatment may be relevant in every contact with a particular patient, 
disease severity and prognosis may only require occasional reassessment. 
This adds relevance to the basic concept of GOLD, which has made disease 
staging the starting point of treatment recommendations.1 Compared with 
patients with more severe COPD, it seems that the majority of patients with 
mild-to-moderate disease do not yet exhibit reduced exercise tolerance, or 
loss of body mass30 or frequent exacerbations.31 For this reason, it would 
make sense to recommend some monitoring procedures, especially the 
monitoring of symptoms and smoking status, as routine for every patient 
with COPD, and apply additional surveillance on the basis of disease 
severity stage. This would not only help to tailor care to the individual 
patients, but also prevent a lot of effort and resources being used for the 
routine collection of information that has no direct relevance to the 
management of the patient.  
 
A baseline severity staging at the time of diagnosis followed by 
reassessment once every few years in patients with mild-to-moderate 
disease may well be sufficient. Based on the disease stage and other 
patient-related factors (e.g., the presence of comorbid conditions), 
monitoring of exercise tolerance, loss of fat-free body mass or frequent 
exacerbations could be adjusted. 
 
This will preserve time, equipment, and facilities for those individuals in 
greatest need, an aspect that is particularly relevant given the fact that the 
number of patients with chronic obstructive pulmonary disease will 
continue to increase in years to come.32  
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At the same time, researchers should take up the challenge to establish 
further evidence of the benefits and cost of monitoring patients with 
chronic obstructive pulmonary disease in well-designed studies. After all, if 
monitoring chronic obstructive pulmonary disease is crucial for facilitating 
optimal patient care, do evidence-based chronic obstructive pulmonary 
disease guidelines not deserve an evidence-based paragraph on 
monitoring?  
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ABSTRACT 
Background: The goals for the management of COPD are to delay the 
process of disease progression and alleviate its manifestations. The follow-
up of the patients’ physical and mental condition is part of best practice 
management when monitoring routines results in information that 
contributes to the achievement of management goals. However, the  
recommendations on monitoring procedures may differ between 
guidelines and may not be based on scientific evidence. The aim of this 
article is to review the current guideline recommendations on monitoring 
routines for COPD. 
Methods: Clinical practice guidelines on the management of COPD were 
identified by a Medline search, Internet search and expanded by experts in 
the respiratory field. Guidelines on the management of COPD were 
analysed on recommended monitoring routines, recommended frequency 
of monitoring. 
Results: Eighteen clinical practice guidelines on the management of COPD 
were analysed. The follow-up of lung function indices was the most 
frequently recommended monitoring routine. Moreover, monitoring of 
symptoms, exercise tolerance, comorbidity, and smoking habits were 
recommended regularly. In none of the guidelines, the recommended 
monitoring routines were evidence-based. Only one guideline provides a 
different set of monitoring parameters for advanced COPD compared to 
mild and moderate COPD. 
Conclusion: Some monitoring routines were recommended frequently, 
especially follow-up of lung function indices. However, evidence to 
support the guideline recommendations for the monitoring of patients with 
COPD is missing. The effect of monitoring on care process and outcomes 
should be assessed.  
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hronic obstructive pulmonary disease (COPD) is a chronic 
condition that, by definition, is not amenable to cure. Therefore, 
the goals for the management of COPD are to delay disease 
progression and alleviate its manifestations.1 Periodic assessments that 
guide the management of a chronic or recurrent disease is usually called 
‚monitoring‛.2 The follow-up of the patients’ physical and mental 
condition is part of best practice when this results in the achievement of the 
management goals.3 Monitoring should therefore be based on markers of 
disease progression that truly predict outcome of disease and guide 
interventions to improve outcome. This would require a scientific evidence 
base of ‚monitored markers‛.4 The latest revision of the global strategy for 
the diagnosis, management, and prevention of chronic obstructive 
pulmonary disease (GOLD-guideline) includes a paragraph on monitoring 
of the disease.5 Moreover, over the past few years, several other clinical 
practice guidelines (CPGs) on the management of COPD have been 
published with directives on monitoring the status and prognosis of 
COPD.6–8 The reality is, however, that not all recommendations are 
evidence-based and that most CPGs contain additional ‚opinion-based‛ 
recommendations. 
We previously reflected on monitoring routines as currently recommended 
in clinical COPD guidelines, and how opinion-based recommendations 
may not necessarily result in clinical benefits or even cause an unnecessary 
physical or mental burden for patients, and an economic burden for the 
society at large.9 An overview of guideline recommendations regarding 
monitoring COPD patients is currently lacking. In this article, we review 
current COPD guidelines’ recommendations on monitoring routines, the 
recommended frequency of the monitoring visits, and the level of scientific 
evidence of the recommendations. 
 
  
C 
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METHODS 
To identify CPGs on the management of COPD, a Medline search was 
carried out using the terms ‚COPD‛ (exploded) and ‚guideline‛. The 
treatment guideline links on the Pubmed site were searched on CPGs on 
the management of COPD (for instance, www.nelh.nhs.uk, and National 
Guideline Clearinghouse). Moreover, an Internet search engine 
(GoogleTM) was used to search for additional CPGs. Finally, experts in the 
field of COPD disease management were asked to complete the list of 
guidelines. Only CPGs that addressed the integral management of COPD 
from diagnose on to treatment and (terminal) care were selected. CPGs for 
specific subgroups of patients or restricted to a specific aspect were not 
selected. The search was restricted to CPGs written in English or Dutch 
language that had been published or updated after the year 2000 and were 
still accurate at the time of our analysis. Table 2.1 shows the characteristics 
of the selected CPGs, including the title, the year of the latest update, and 
the organisation responsible for its development. More information on the 
CPGs (e.g., its clinical goal, definition of COPD, the professional groups 
included in development and target users) is described in an online data 
supplement (see online data supplement). Monitoring of chronic disease 
was defined as the process of periodically assessing, observing, recording 
and/or testing of certain aspects of a patient’s physical and mental 
condition.10 Consequently, all recommendations on periodic collection of 
data about the physical and/or mental condition of patients were listed as 
monitoring routines. 
 
General recommendations regarding monitoring of COPD patients were 
searched, like whether or not an hierarchic evidence grading system had 
been applied for the recommendations in the CPGs, if the monitoring 
recommendations were actually evidence graded, and whether or not there 
is a separate paragraph on monitoring included in the CPG. Moreover, the 
full text of each CPGs was analysed to identify all aspects that should be 
monitored or be part of follow-up visits of patients by one of the authors 
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(LB) and independently verified by a second author (TS). Next, the search 
function in the text processing program was used to crosscheck for terms 
like monitor*, follow-up and audit* (or Dutch equivalents when applicable) 
in the CPGs. All monitoring routines recommended by the CPGs are given 
in Table 2.2. The monitoring routines that were recommended by more 
than a third of the CPGs (n ≥ 7) are described in Table 2.3. Monitoring 
routines that were implied but not specifically recommended were graded 
with a +/- sign. 
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RESULTS 
Clinical practice guidelines on the management of COPD 
Nineteen CPGs on the management of COPD were identified that had been 
published or updated after the year 2000 and fulfilled the other inclusion 
criteria. One CPG was excluded because it only consisted of three written 
pages with no literature references.11 The remaining 18 CPGs were screened 
regarding the recommended monitoring routines. Characteristics of the 
CPGs are given in Table 2.1 and the online data supplement. One CPG did 
not give any recommendations regarding monitoring routines.12 Twelve 
CPGs (67%) included a separate paragraph on monitoring disease or 
follow-up visits.5–8,13–20 
 
Recommended monitoring routines 
Sixteen of the CPGs (89%) recommended monitoring of lung function 
(Table 2.2). When a definition of lung function monitoring was given in the 
guidelines, it was always the spirometric measurement of the (change in) 
FEV1 (forced expiratory volume in 1 second), sometimes combined with a 
recollection of information on the FEV1/FVC ratio. Monitoring of 
symptoms, exercise tolerance, comorbidity, exacerbations, inhaler 
technique, and smoking habits were recommended by at least half of the 
CPGs. There was large agreement on recommended monitoring routines 
between the NICE, CBO, GOLD, CKS, COPD-X, ABFP, and NHG 
guidelines (Table 2.3).5–7,15,16,18,20 Additionally, the ATS/ERS standards for the 
diagnosis and management of patients with COPD recommend that the 
‘‘intensity’’ of follow-up visits should be based on the patient’s disease 
status and course, though without providing specific recommendations.8 
The NICE guideline is the only guideline that recommends a different set of 
monitoring routines for patients with mild or moderate COPD compared to 
patients with severe disease.6 For example, nutritional state and oxygen 
saturation should only be monitored in patients with severe COPD.6 
 
  
Table 2.1.  Description of the characteristics of the selected clinical practice guidelines for chronic obstructive pulmonary disease. 
 
  
Abbrevia-
tion 
Organisation Year* Country / 
region 
Title in English Evidence 
grading 
(EG) 
EG 
monitoring 
GOLD Collaboration of many organisations 
including American Thoracic Society, 
European Respiratory Society and 
World Health Organisation 
2006 Global Global strategy for the diagnosis, 
management, and prevention of 
chronic obstructive pulmonary 
disease. 
+ - 
ATS/ ERS American Thoracic Society and 
European Respiratory Society 
2004 Global Standards for the diagnosis and 
treatment of patients with chronic 
obstructive pulmonary disease. 
- - 
IPAG International Primary care Airway 
Group 
2004 Global Chronic airway diseases; a guide for 
primary care physicians 
- - 
IPCRG† International Primary Care Respiratory 
Group 
2006 Global International Primary Care 
Respiratory Group (IPCRG) 
Guidelines: management of chronic 
obstructive pulmonary disease 
(COPD) 
+ + 
EBM Duodecim medical publications Ltd 2004 Global Evidence-based medicine guideline; 
chronic obstructive pulmonary 
disease 
+ - 
COPD-X The Thorax Society for Australia and 
New Zealand and the Australian Lung 
Foundation 
2007 Australia/ 
new 
Zealand 
Chronic obstructive pulmonary 
disease (COPD) Australian and New 
Zealand management guidelines and 
the COPD handbook (COPD-X) 
+ - 
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Table 2.1.  Continued 
 
 
 
Abbrevia-
tion 
Organisation Year* Country / 
region 
Title in English Evidence 
grading 
(EG) 
EG 
monitoring 
CTS Canadian Thoracic Society 2004 Canada Canadian Thoracic Society 
recommendations for the 
management of chronic obstructive 
pulmonary disease 
+ - 
BCMA British Columbia Medical Association 2007 Canada Chronic obstructive pulmonary 
disease (COPD) 
- - 
India WHO (India) 2003 India Guidelines for management of 
chronic obstructive pulmonary 
disease (COPD) in India: A guide for 
physicians 
- - 
CBO Collaboration of many organisations 
including Dutch College of General 
Practitioners and Dutch Institute for 
Health Care (CBO) 
2005 Netherlands Guideline integrated care COPD + + 
NHG Dutch College of General Practitioners 2007 Netherlands NHG-standard COPD - - 
PA Palestinian Ministry of Health 2003 Palestinian 
region 
Palestinian guideline for diagnosis 
and management of chronic 
obstructive pulmonary disease 
- - 
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Table 2.1.  Continued  
GOLD: Global Initiative for Chronic Obstructive Lung Disease, WHO: World Health Organization, EBM: Evidence-Based Medicine Guidelines, CBO: Dutch Institute for Healthcare 
Improvement , *  Either the year of initial publication or, in case of periodic update of the guideline, the year of the most recent update, †  IPCRG and IPAG guideline are developed by 
the same group of experts. 
Abbrevia-
tion 
Organisation Year* Country / 
region 
Title in English Evidence 
grading 
(EG) 
EG 
monitoring 
SA South African Thoracic Society 2004 South-Africa Guideline for the management of 
chronic obstructive pulmonary 
disease (COPD) 
- - 
SRS Swiss Respiratory Society 2002 Swiss Management of chronic obstructive 
pulmonary disease: the Swiss 
guidelines 
+ - 
CKS National health service and 
department of health United Kingdom 
(UK) 
2007 UK Clinical knowledge summaries 
(converted from Prodigy guidance) 
chronic obstructive pulmonary 
disease 
+ + 
NICE National Collaborating Centre for 
Chronic Conditions. 
2004 UK National clinical guideline on 
management of chronic obstructive 
pulmonary disease in adults in 
primary and secondary care 
+ - 
ISCI Institute for Clinical System 
Improvement United States of America 
(USA) 
2007 USA Health Care guideline; chronic 
obstructive pulmonary disease 
+ - 
ABFP American Board of Family Practice 2001 USA Reference guide COPD - - 
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Table 2.2.  Monitoring routines recommended by one or more of the selected clinical practice 
guidelines for chronic obstructive pulmonary disease (COPD). 
Monitoring routines Number of guidelines (n=18) 
Lung function 16 
Symptoms / dyspnoea  15 
Smoking habits 13 
Exercise tolerance 11 
Comorbidity / complications 11 
Exacerbations 11 
Inhaler technique 9 
Side effects of treatment 8 
Effect of drug treatment  8 
Nutritional condition 8 
Compliance with treatment 8 
Theophylline levels in blood if prescribed 6 
Quality of life / health status 6 
Arterial blood gasses 5 
Hospital admissions 4 
Symptoms control 4 
Physical examination 3 
Psychosocial disorder / depression  3 
Limitations caused by COPD 2 
Need for adjustments in work situation 2 
Need for long-term oxygen therapy (LTOT) 2 
Health care need 1 
Need for referral to lung physician 1 
Need for pulmonary rehabilitation 1 
Need for other therapies 1 
 
Frequency of monitoring visits 
Six CPGs (33%) did not provide any information on the frequency of 
follow-up visits;13,15,21–26 three CPGs (17%) indicate that the frequency of 
monitoring visits should depend on the local health care system;5,8,14 and 
nine CPGs (50%) recommend that the number of visits should be tuned to 
the disease severity and progression of the individual patient.5–8,14,16,17,19,20 
Eight CPGs provide suggestions for the frequency of monitoring visits that 
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vary between monthly to yearly.5–7,16–20 Moreover, one CPG (CBO) 
recommended monitoring of lung function in a lower frequency than other 
monitoring routines, i.e., once every three years.7  
 
Evidence grading monitoring recommendations 
Nine CPGs (50%) provided information regarding the level of evidence for 
management recommendations.5–7,12,14,15,19,21,22,26 Usually the evidence was 
graded from the highest level of evidence: A (evidence resulted from 
several well-designed randomised clinical trials) till the lowest level of 
evidence: D (expert opinion).27 Only three CPGs—the CBO, IPCRG and 
NICE guidelines—used an evidence grading system for some of their 
specific monitoring recommendations.6,7,14 According to these guidelines, 
there was no scientific evidence for any of the monitoring 
recommendations (i.e., all monitoring recommendations were based on 
expert opinion). 
 
  
Table 2.3.  Recommendations on monitoring routines by clinical practice guidelines for chronic obstructive pulmonary disease (COPD).  
Monitoring parameters NICE CBO IPCRG GOLD EBM CKS ICSI CTS COPD-X 
Lung function + + + + - + + + + 
Symptoms / Dyspnoea  + + + + - + - + + 
Smoking habits + + +/- + - + + +/- + 
Exercise tolerance + + +/- - - - - - - 
Comorbidity / complications + + +/- + - + + - + 
Exacerbations + + +/- + - + - - + 
Inhaler technique + + - + - + - - + 
Side effects treatment + + + + - - - - + 
Effect of drug treatment  + + - + - + + - + 
Nutritional condition + + - - - + - - + 
Compliance with treatment - + + + - + - - + 
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Table 2.3.  Continued 
Monitoring parameters SRS ATS/ERS IPAG ABFP NHG BCMA India SA PA  Number of 
guidelines 
Lung function - + +/- + + + +/- + + 16 
Symptoms / Dyspnoea  +/- + +/- + + - +/- +/- + 15 
Smoking habits - + - + + - +/- - + 13 
Exercise tolerance +/- + +/- + + - - +/- + 11 
Comorbidity / complications - + - + + - +/- - - 11 
Exacerbations - +/- - + + + +/- - - 11 
Inhaler technique - - - + + - - + - 9 
Side effects treatment - - - + + - - - + 8 
Effect of drug treatment  - - - + + - - - - 8 
Nutritional condition - + - + + - - +/- - 8 
Compliance with treatment - - - + + - - - + 8 
+ monitoring routine recommended in CPG, +/- item was mentioned in CPG, but unclear for reviewers if it was meant to be a monitoring procedure, monitoring routine not mentioned 
in CPG. 
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DISCUSSION 
This review identified 19 CPGs on the management of COPD of which 18 
were analysed on recommendations concerning disease monitoring in 
patients with COPD and the evidence behind these recommendations. The 
follow-up of lung function was the most frequently recommended 
monitoring routine. Symptoms, smoking habits, exercise tolerance, and 
comorbidity were also frequently recommended. However, none of the 
guidelines provided scientific evidence for their recommended monitoring 
routines. This implies that there is scant evidence that the defined ‚best 
practice‛, is in the best interest of the patients with COPD. In appraising 
our findings, more emphasis should be placed on the nature of the 
information to be monitored. None of the guidelines we reviewed made the 
distinction between ‚direct‛ monitoring of outcome of care—for example, 
symptom relief, or smoking cessation—and the monitoring that predicts 
the prognosis and of long-term outcome of care.  
 
As discussed elsewhere, measuring the direct outcome of care is usually 
self-evident, but monitoring the long-term course is based on markers of 
disease progression (pulmonary function; body mass index (BMI)) and in 
this evidence of its predictive value and therapeutic implications are 
essential.9 Some monitoring procedures like monitoring dyspnoea can 
serve several goals (i.e., facilitate COPD management decision making and 
provide information on disease progression). Below, we review the nature 
of the recommended monitoring  procedures based on literature.  
 
Smoking cessation is the only intervention that could reduce the lung 
function decline of patients with COPD.28 Smoking cessation also relieves 
symptoms and reduces mortality.29 Though difficult to achieve, there are 
opportunities to improve the success rate of smoking cessation.30 Therefore, 
monitoring of smoking status is important to identify smoking cessation 
opportunities, thereby improving disease status in short term (i.e., direct 
monitoring) and delay disease progression. Also, identifying symptoms is 
important to direct therapy. Symptoms are the patients’ subjective 
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perception of disease manifestation and symptom relieve should have a 
prominent place in the management of COPD.5 Pharmacological therapy, 
smoking cessation, and pulmonary rehabilitation can reduce symptoms.31–33 
Moreover, various interventions can reduce the number of (hospitalised) 
exacerbations; use of inhaled corticosteroids, the use of a long acting 
bronchodilators, and self-management.34–37 Exacerbations impairs quality of 
life and cause frequent hospital admissions and increased health care costs, 
especially in patients with more severe COPD.38–40 Early introduction of 
treatment for exacerbations resulted in faster recovery of the exacerbation.41 
Therefore, the evaluation of the pattern of exacerbations as a part of 
periodic monitoring could lead to improved care. Next, using medication 
in an appropriate way seems essential to have optimal benefits of treatment 
with minimal side effects of therapy (i.e., monitoring inhaler technique, 
effect and side effects of drug treatment). For example, most COPD 
medication is delivered by inhalers, which reduces systematic side effects, 
but about a quarter of patients with COPD make at least one essential 
mistake when using their inhaler device.42 Good inhaler technique has been 
related to symptom relieve, improve quality of life, reduce exacerbations, 
and improve exercise tolerance.31,35 Instructions and educational programs 
can improve the inhaler technique of patients with COPD.43,44 
Moreover, patients with COPD frequently suffer from comorbid conditions 
and complications. Over 20% of COPD patients in a primary care 
population had undiagnosed congestive heart failure.45 Identifying 
comorbidity and complications could lead to (early) treatment and 
improved disease course or disease state by timely initiation of 
interventions that are not directly related to COPD (e.g., treatment of heart 
failure with diuretics, vasodilator therapy, and treatment with inotropic 
agents). Finally, exercise capacity, often assessed by establishing the 6 min 
walking distance (6MWD), is influenced by lung capacity but also by 
extrapulmonary effects of COPD like diminished skeletal muscle strength.46 
Research on the effectiveness of pulmonary rehabilitation has shown 
improvements on various outcomes, like the exercise capacity test, quality 
of life, prognosis, and incidence of comorbidity.47  
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Monitoring exercise tolerance could be useful to identify the patients that 
could benefit most from this intervention. 
In addition to dyspnoea, lung function and exercise tolerance, the BMI may 
predict survival in patients with COPD (i.e., prognostic monitoring).48 
Involuntary weight lost is associated with increased dyspnoea, impaired 
quality of life and less exercise tolerance in severe COPD.49,50 The effect of 
caloric supplementation on different outcomes like anthropometrical 
measures and exercise capacity in patients with stable COPD was found to 
be small and insignificant in a recent meta-analyses of published studies.51 
So no clear statement can be made on the value of monitoring BMI in case 
of COPD. 
What is more, the most frequently recommended monitoring routine—lung 
function (i.e., assess FEV1 change)—has primarily an informative character, 
without therapeutic implication since no present therapy other than 
smoking cessation was found to modify the lung function decline in 
patients with COPD. However, spirometric testing remains essential to 
diagnose COPD and provides information on an important aspect of 
disease severity and progression.48 As the disease progresses, periodic 
reassessment of the severity of airflow obstruction enables the selection of 
stage-specific treatment recommendations, like the treatment with an 
inhaled steroid to prevent exacerbations, which is only recommended for 
patients with a FEV1 below 50% of the predicted value.52 Moreover, a small 
improvement on lung function status was found when interventions were 
introduced, like the use of bronchodilators.31 
 
Only two-third of the CPGs included a specific paragraph on monitoring 
COPD. The majority of CPGs that comprise recommendations on 
monitoring frequency recommend that the number of visits should be 
tuned to the severity and course of disease of each particular patient. In 
contrast to the number of monitoring visits, CPGs recommendations 
regarding monitoring routines did not differ between patients with 
different stages of disease severity, except in the NICE guideline.6 Several 
routines may not be applicable to the patients with mild or moderate 
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COPD, like the monitoring of arterial oxygen saturation, whereas these 
patients make out the vast majority of the COPD patient population.53 
Moreover, it is remarkable to see that the recommended frequency of 
performing does usually not differ between the recommended routines, 
despite the fact that there are important differences in the relevance of the 
acquired information, costs of the routines/measurements, and their burden 
for the patients. Although good follow-up is essential to achieve the 
optimal level of COPD patient care, the attention paid to monitoring in 
most CPGs is limited. To a certain extent this may be the result of the 
complete lack of well-designed studies on this topic, especially in contrast 
to other areas of COPD disease management like, for instance, 
pharmacotherapy. We suggest that studies on monitoring of COPD should 
focus on those routines that are not self-evident and result in considerable 
burden for the patient and/or society. For instance, evidence should be 
collected on the value of regular lung function monitoring and the effect of 
monitoring the exercise tolerance in patients with mild-to-moderate COPD. 
The effectiveness of these monitoring routines should be evaluated on 
clinical benefits for the patients like a reduction of symptoms, and 
improvement of quality of life. 
 
Some methodological considerations warrant mentioning. 
This overview was limited to CPGs written in Dutch and English and 
consequently do not provides an overview of all guidelines developed 
worldwide. What is more, since CPGs are updated regularly and new 
scientific evidence becomes available continuously, the results in this article 
must be seen as a ‘freeze-frame’. Next, it was not always clear whether or 
not the procedure was a monitoring routine in the eyes of the authors of the 
CPGs. On the other hand, it might be that monitoring routines cannot be 
recognised as such, because of the formulation in the CPG. For example, all 
CPGs emphasised smoking cessation, with the recommendation to inquire 
after the patients smoking status. However, the subsequent periodic review 
of smoking status was not always recommended. In this study, we 
focussed on the monitoring recommendations in the CPGs. Therefore, the 
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quality of the whole CPGs was not assessed according to the AGREE 
procedure.54 The essential information on the CPGs, including the evidence 
grading system, was described in the online data supplement. 
 
In conclusion, gathering information on some of the recommended 
monitoring parameters, like smoking status, symptoms, and inhaler 
technique may serve an obvious treatment purpose. At this time, 
insufficient information is available to assure that the collection of this data 
results in better management of patients with COPD. Therefore, it is not 
possible to formulate conclusive advices on the usefulness or benefits of 
guideline recommended monitoring routines for patients with COPD. An 
evidence-based approach on monitoring of patients with COPD seems 
essential in order to provide and maintain the best possible evidence-based 
and efficient care. Moreover, evidence-based monitoring recommendations 
—not only the frequency but also the selected monitoring routines— 
should preferably be tuned to the disease severity level of the patient. 
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ABSTRACT 
Aim: The objective of our study was to explore the (co-)existence of factors 
that were recommended by the American Thoracic Society (ATS)/European 
Respiratory Society (ERS) standard for staging patients in a primary care 
COPD population. 
Methods: A representative sample of COPD patients in primary care was 
studied. Cross-sectional, information on airflow obstruction, body mass 
index (BMI), and dyspnoea (MMRC score) were collected. The (co-) 
existence of these prognostic factors was described.  
Results: The study sample consisted of 2,023 patients. BMI was low in 
11.7%, MMRC score ≥ 2 was found in 28.7%, and 53.9% fulfilled the criteria 
of relevant airflow obstruction. Only 3.4% of this population scored on all 
three prognostic factors. 
Conclusion: Moderate dyspnoea and moderate airflow obstruction were 
rather prevalent in this primary care population, but coexistence of factors 
was low. Therefore, it seems that the assessment of BMI and dyspnoea 
represent additional information of primary care COPD patients. 
   
 The (co-)existence of prognostic COPD factors 
   
57 
raditionally, chronic obstructive pulmonary disease (COPD) is 
diagnosed and classified based on spirometric assessment only.1 
However, the majority of patients with COPD in primary care are 
categorised in GOLD stages 1 or 2, while their levels of functional 
impairment and prognosis may differ substantially.2 Therefore, the 
American Thoracic Society (ATS)/European Respiratory Society (ERS) 
guideline for the diagnosis and management of patients with COPD 
recommend a staging system that presents a composite picture of disease 
severity.3 According to these recommendations, assessment of COPD 
severity comprises measurement  of FEV1, level of dyspnoea and Body 
Mass Index (BMI) in all patients.3 Multicomponent staging tools for COPD 
like the BODE index (BMI, Obstruction, Dyspnoea, and Exercise tolerance), 
COPDSS (COPD Severity Score), and CPI (COPD Prognostic Index) have 
recently been developed, all of which consisting of some of the 
aforementioned disease severity components.4-6 The BODE index and CPI 
were found to be better predictors of mortality than FEV1 alone.4,5 
However, empirical evidence on disease severity components and 
multicomponent staging tools comes from studies performed in secondary 
and tertiary care settings. Only for the COPDSS, the validity has been 
assessed in a primary care COPD population, but this particular instrument 
does not contain staging factors recommended by the ERS/ATS guideline 
(i.e., BMI and FEV1).6,7 
 
From a primary care perspective there is a concern that the spectra of the 
predominant severity components in the staging tools are strongly skewed 
towards mild outcomes. If that is indeed the case, the staging tools will not 
be able to discriminate disease severity levels in primary care COPD 
patient populations. Only one study has described the prevalence of high 
dyspnoea scores and low BMIs in primary care COPD patients.8  
  
T 
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However, this study included participants of a trial examining an 
outpatient disease management program,8 whereas a large and 
representative patient sample is needed to study the full spectrum of 
COPD severity levels in primary care. Moreover, information on the co-
occurrence of severity components is needed to determine the necessity to 
collect information on all individual severity components. In the study 
reported in this paper we investigated  (i) the prevalence, and (ii) the 
coexistence of low BMI, moderate or severe dyspnoea, and moderate or 
severe airflow obstruction in a large representative population of COPD 
patients managed  in Dutch general practices.   
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METHODS 
Study population and selection of patients 
Our study was a cross-sectional study based on available data from a 
regional primary care diagnostic centre in the South-western part of the 
Netherlands (the ‘Stichting Huisartsen Laboratorium Etten-Leur’ (SHL)). 
Details of the SHL diagnostic centre, procedures, and database are 
described elsewhere.9,10 Briefly, lung function technicians of the SHL 
support general practitioners’ (GP) management of patients with COPD 
through monitoring of respiratory health data and compilation of feedback 
reports. The monitoring consists of repeated, standardised assessment of 
lung function, body weight, height, dyspnoea and other symptoms, 
smoking status, medication use, and exacerbation history.  
 
Figure 3.1 describes the selection procedure of patients with COPD from 
the SHL database. We selected data from May 2004 until May 2006. In case 
a patient had more than one test in the database, the most recent test was 
selected. Patients < 40 years of age and patients with a postbronchodilator 
FEV1/FVC ≥ 0.70 were excluded, as were cases with missing data.  
 
Measurements and outcomes 
Pre- and postbronchodilator forced expiratory volume in 1 second (FEV1) 
and forced vital capacity (FVC) were measured with an electronic 
spirometer (SpiroPerfect®, WelchAllyn, Delft, The Netherlands). FEV1 as 
percentage of the predicted value (FEV1% predicted) was calculated using 
reference equations from the European Community for Coal and Steel 
(ECCS).11 Lung function technicians assessed patients’ height and weight at 
every visit. BMI was defined as the patient’s body weight divided by the 
squared height. Dyspnoea was inquired using the Modified Medical 
Research Council (MMRC) Questionnaire.12  
 
  
Chapter 3 
  
60 
Figure 3.1. Flow chart of patient selection in the study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* To assure a current population and uniform collection of information, † Postbronchodilator, 15 min after 
administration of 400 μg aerosolized salbutamol through spacer, ‡  Patients ≥ 40 years of age with a postbronchodilator 
FEV1/FVC ratio < 0.70, ¶ 98 missing values BMI, 13 missing values MMRC, 12 missing values  smoking, 29 missing 
values pack-years, 12 missing values exacerbations, 25 missing values medication use (Some patients were excluded 
based on multiple missing values).  
 
 
Initial set of all lung function tests 
(n = 48,808) 
Excluded tests (n = 20,924) 
Selection of most recent test per patient 
Sample of a single test per patient 
(n = 27,884) 
Excluded tests (n = 18,605) Exclude: tests <May 2004* 
Cross-sectional sample of patients 
(n = 9,279) 
Excluded patients (n = 7,109) Exclude: patients < 40 yrs and 
FEV1/FVC ≥ 0.70† 
Cross-sectional sample of COPD patients  
(n = 2,170)‡ 
Excluded patients (n = 147) Exclude: patient with missing data
¶ 
Analysed study sample 
(n = 2,023) 
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Analysis 
The characteristics of the study population and prevalence of low BMI, 
level of dyspnoea, and airflow obstruction classified according to the 
criteria in the ATS/ERS guideline were described.3 Since the ATS/ERS 
guideline does not provide information on prognostic thresholds of MMRC 
score and airflow obstruction, we used the empirical model for computing 
the BODE score to calculate interaction between the severity components.4 
We used an area-proportional Venn diagram to visualise the (co-)existence 
of a low BMI (<21 kg/m2), dyspnoea (MMRC score ≥ 2), and airflow 
obstruction (FEV1 ≤ 64 % of predicted) in our study sample. The best fitted 
area-proportional Venn diagram was designed using 3Venn Applet 
software (http://www.cs.kent.ac.uk/people/staff/pjr/EulerVennCircles/ 
EulerVennApplet.html).13 Correlations between the three prognostic factors 
(BMI, MMRC score, airflow obstruction) were tested with the Kendall tau-b 
test. r < 0.3 was considered a weak correlation, r between 0.3 and 0.7 a 
moderate correlation, and r > 0.7 a strong correlation. P-values used in the 
analyses are two-tailed and differences with p < 0.05 were considered 
statistically significant. The Statistical Package for Social Sciences (SPSS 
version 14.0.0, Chicago, USA) was used for the analysis. 
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RESULTS 
Patients 
The final study population consisted of 2,023 patients. The characteristics of 
the study sample are given in Table 3.1. Overall, 61.8% of all patients were 
males and 43.7% were current smokers.  
 
Severity components 
Of the total population, 76.4% had a mild-to-moderate severe airflow 
obstruction (i.e., FEV1 ≥ 50 % of predicted) and 46.1 % did not fulfil the 
prognostic ‚obstruction‛ criteria (i.e., FEV1 ≤ 64 % of predicted). Only 2.5 % 
of the sample was classified as GOLD stage IV. Table 3.1 shows that BMI 
was low (≤ 21) in 11.7% of the population. A MMRC score of 2 or higher 
was found in 28.7% of the sample; prevalence of MMRC scores 3 and 4 
were very low (MMRC score 3: n=58, 2.9%; MMRC score 4: n=14, 0.7%). 
Overall, 64.4% of all patients showed a limitation in one severity 
component (either airflow obstruction, or low BMI, or dyspnoea according 
to the MMRC), while 23.1% scored on two components, and 3.4% scored on 
all three components. The overlap of severity components is visualised in 
Figure 3.2. Correlations between BMI and FEV1 categories and between 
MMRC score and BMI were weak (r=0.03 and r=0.08, respectively). The 
correlation between the FEV1% of predicted categories and MMRC scores 
just reached the lower limit of a moderate correlation (r = 0.30). 
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Table 3.1.Characteristics and disease severity components of the COPD patient study 
sample (number with percentage, except when stated otherwise). 
 
COPD-population 
(n = 2,023) 
Age*      62.8 (10.8) 
Gender (male) 1,250 (61.8) 
Airflow obstruction (Post-BD FEV1 % predicted)   
  ≥ 80    289 (14.3) 
  50 – 80 1,256 (62.1) 
  30 – 50    427 (21.1) 
  < 30      51 (  2.5) 
Dyspnoea (MMRC score)   
  0    623 (30.8) 
  1    819 (40.5) 
  2    509 (25.2) 
  3 or 4      72 (  3.6) 
Low weight (BMI)   
<   21 kg/m2    237 (11.7) 
>= 21 kg/m2 1,786 (88.3) 
Cigarette smoking   
   never    261 (12.9) 
  former smoker    878 (43.4) 
  current smoker    884 (43.7) 
Packyears*      26.8 (18.8) 
Use of respiratory medication   
None    490 (24.2) 
Short-acting bronchodilator    767 (37.9) 
Long-acting bronchodilator    965 (47.7) 
Inhaled corticosteroids 1,115 (55.1) 
Postbronchodilator lung function   
FEV1*        1.95 (  0.7) 
FEV1% of predicted*      62.5 (16.4) 
FEV1/FVC %*      58.8 (  9.5) 
Exacerbations in past 12 months  
  Yes    727 (35.9) 
  No 1,296 (64.1) 
Number of exacerbations   
  1    538 (26.6) 
  ≥ 2    189 (  9.3) 
* mean (SD). 
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Figure 3.2. Venn diagram of percentages of primary care COPD patients (n=2,023) that 
fulfilled the severity component criteria for Body Mass Index (<21), Airflow 
Obstruction (FEV1% of predicted < 65), and / or Dyspnoea (MMRC ≥ 2) resulting 
in increased mortality risk according to the BODE index. 
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DISCUSSION 
Summary of findings 
In order to explore the usefulness of factors that were recommended by the 
ATS/ERS standard for prognostic staging patients with COPD we have 
described the (co-)existence of three components of disease severity as 
recommended by the ATS/ERS COPD guideline in a large and 
representative primary care COPD patient sample. Some of the individual 
components, especially a FEV1 between 50 and 80% of predicted and 
MMRC score 2, were prevalent. The coexistence of severity components 
was low. 
 
Comparison with previous studies 
In this study, 76% of the patients with COPD were classified as mild-to-
moderate COPD according to the criteria for airflow obstruction, which is 
comparable to the findings of Hoogendoorn (82%) and Steuten (78%).1,8 
Also, the prevalence of MMRC score 2 and low BMI were quite comparable 
with the study by Steuten et al. (30%, 12% in their sample).8  
 
Prognostic thresholds 
We used the thresholds of the BODE index to examine the coexistence of 
prognostically relevant underweight, dyspnoea, and airflow obstruction. 
The BODE index has become widely accepted as a staging/classification 
tool to predict prognosis in patients with COPD in secondary and tertiary 
care.4 This instrument was found to be a strong predictor for mortality in 
COPD patients with advanced disease.4 Another multidimensional grading 
system for COPD, the CPI, was suggested by Briggs et al.5 Their instrument 
includes other prognostic factors like health related quality of life, history 
of exacerbations, cardiovascular comorbidity, age and gender. The CPI was 
not only able to predict mortality, but also hospitalisations and 
exacerbations.5 Another recently published instrument, the COPDSS,  
incorporates clinical aspects of the disease, including respiratory 
symptoms, oral corticosteroid use, other COPD medication use, previous 
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hospitalization and intubation, and home oxygen therapy.6,7 Not 
surprisingly, the COPDSS score was associated with degree of dyspnoea 
and number of exacerbations.6 Since the instrument was developed for use 
in a telephone survey, the instrument does not contain components that 
need biomedical measurement like BMI and FEV1. From a primary care 
perspective, all these instruments have pros and cons. The inclusion of 
health related quality of life as prognostic factor and predicting outcome 
like exacerbations are attractive aspects of the CPI. The COPDSS is the only 
instrument that has been validated in a primary care COPD population and 
was associated with outcomes relevant for a primary care patients. Still, we 
chosen the thresholds of the BODE index in our study for two reasons. 
First, the BODE index is the only instrument that comprises all three factors 
recommended by the ATS/ERS standard. Secondly, the cutoff value for 
underweight in the BODE index (<21 kg/m2) fits the ATS/ERS guideline 
recommendations, whereas the cutoff value of the CPI (BMI < 20) does not. 
In addition, the CPI has a more stringent cutoff value for airflow 
obstruction (FEV1 < 60 % of predicted). Had we used the CPI cutoff values, 
a smaller number of  patients would have fulfilled the severity component 
criteria (i.e., n=148 (7.3%) fulfil the CPI underweight criterion, and n=886 
(42.8%) fulfil the CPI airflow obstruction criterion).  
 
Multicomponent staging tool 
The ATS/ERS guideline suggests that a staging system that offers a 
composite picture of disease severity is highly desirable.3 The BODE index 
has been suggested as a practicable evidence-based staging system for all 
patients with COPD.4 In this study, we examined three of the four BODE 
components and in this population the overall mean BODE-score of these 
three components was 1.27 (95%CI, 1.22-1.33 on a scale from 0-7). We found 
that high scores on the BODE index are rare and variation in score is low in 
primary care COPD patients. Therefore, the BODE index seems of little 
value to discriminate between disease severity levels in primary care. 
However, without information on the fourth component of the BODE index 
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(Exercise tolerance assessed with the six minute walking distance (6MWD) 
test) this remains an assumption that needs to be verified. Observations on 
the distance that patients with relative mild disease, as seen in primary 
care, can walk in six minutes have not been published yet. Therefore, 
information on the 6MWD from a representative primary care COPD 
patient sample is urgently needed. Moreover, it would be interesting to 
look at the correlation between the 6MWD and the MMRC score. Both 
instuments represent exercise limitation, though the MMRC score is a 
subjective measure (i.e., patients are asked to grade their breathlessness 
according to the level of exercise) while the 6MWD is an objective measure 
(i.e., how far can a patient walk in 6 minutes). Do these components truly 
represent different aspects of COPD or are they both indicators of the same 
characteristic? 
 
COPD severity staging tool for primary care 
Our results underline the multidimensionality of COPD with relevant 
numbers of patients that fulfil the individual criteria for COPD in primary 
care. However, conclusions about the prognostic value of these factors for 
primary care COPD patients cannot be inferred from our findings and 
several questions remain. First, we need to know which outcomes are vital 
for patients with COPD. Usually, severity components are chosen that 
predict mortality risk in COPD patients. Although COPD is one of the 
leading causes of mortality worldwide, for patients it is first and foremost 
an incapacitating disease that can have a strong negative impact on their 
daily life.14,15 Therefore, it may well be that other outcomes, like health-
related quality of life, exacerbations, or hospitalizations are just as relevant 
as mortality risk. Moreover, there should be sufficient variation in the 
selected outcomes within the population of COPD patients. Mortality rate 
in patients with mild-to-moderate severe COPD is very low in general.16 
Secondly, the selected severity components should be prevalent in the 
primary care COPD patient populations and should be able to predict the 
relevant outcome(s) in primary care COPD patients. None of the current 
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multicomponent tools are developed based on information of primary care 
COPD patients, and the predictive capacity of the instruments for primary 
care patients has not been established. However, a study protocol of an 
international collaboration that aims at developing such an instrument has 
recently been published.17  
 
Conclusions and implications for primary care practice 
Relevant numbers of patients fulfil the individual ATS/ERS staging criteria 
in our primary care COPD patient sample. This is especially true for 
‚moderate‛ levels of dyspnoea according to the level of exercise required 
and moderate airflow obstruction. The weak correlation between the 
various severity components underlines the multidimensionality of COPD 
and the necessity to collect uniform information even when disease severity 
of the patient is only considered as mild in terms of airflow obstruction. In 
other words, it seems that the assessment of BMI and dyspnoea represent 
additional information of COPD patients. However the prognostic value of 
this information in primary care warrants further investigation. In our 
view, the development of a COPD severity staging model that takes into 
account all aspects relevant for COPD patients that can be used in primary 
care should be a research priority in the upcoming years.  
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ABSTRACT 
Introduction: Patients with COPD are believed to have a high risk for the 
development of depression. However, it remains unclear whether or not 
there is a temporal relation between COPD and depression, and if the 
higher risk for depression is a result of having a chronic disease, or is 
specific for COPD. The aim of this study is to compare the risk for 
physician-diagnosed depression in patients with COPD, patients with 
diabetes mellitus (DM), and control subjects without chronic conditions.  
Methods: The study was a prospective cohort study based on the 
Continuous Morbidity Registration database. Cox proportional hazards 
analysis was used to identify the risk of a first episode of depression in 
patients with COPD compared to patients with DM and matched control 
subjects without chronic conditions. The following covariates were added 
to the model: age, the general practice the patient was listed with, 
socioeconomic status, comorbidity, and gender. All patients with a 
diagnosis of depression preceding the date of first diagnosis of COPD or 
DM (dummy date in control subjects) were excluded. 
Results: The hazard ratios for a first episode of depression in the COPD 
group compared to the DM group and healthy control subjects were 1.80 
(95% confidence interval [CI], 1.16 to 2.81) and 1.68 (95% CI,1.20 to 2.35), 
respectively.  
Discussion: We found a temporal relation between COPD and physician-
diagnosed depression. Patients with COPD are more likely to have 
depression diagnosed than patients with DM and control subjects without 
chronic conditions.  
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epression is a mental health problem that results in reduced 
health related quality of life, and increased mortality.1-3 Patients 
with chronic diseases in general and those with chronic 
obstructive pulmonary disease (COPD) in particular, are believed to have a 
higher risk of developing a depression compared to healthy individuals.4 
Precise data of depression rate in patients with COPD are lacking: estimates 
range from 6 to 59%.5-12 As COPD is a leading cause of morbidity and the 
prevalence of COPD is increasing, concomitant susceptibility of patients to 
depression is of major concern.13  
 
Most studies have used depression questionnaires in which COPD-related 
symptoms and those indicative of depression may well be entwined and 
unjustly be interpreted as a ‚depression‛.6 More importantly, the temporal 
relation between depression and COPD remains unclear (i.e., does COPD 
enhance the risk for a depression or vice versa?). Moreover, it is not clear if 
depression in patients with COPD is a specific characteristic of this patient 
group, or is a more general feature of patients with a chronic illness. 
Patients with other common chronic conditions like diabetes mellitus (DM) 
are also assumed to be at higher risk for depression.14 Finally, the role of 
comorbid conditions on the relation between depression and COPD is 
unknown. For another chronic condition, DM type II, a larger number of 
coexisting chronic conditions significantly increased the risk of a 
concurrent diagnosis of depression.15 However, for COPD patients, 
comorbidity was not associated with significant higher risk for depression 
in one study.7  
 
The objective of this study was to assess the incidence of first episodes of a 
physician’s diagnosis of depression in patients with COPD and compare 
this with patients with DM and individuals without chronic conditions. 
D 
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MATERIALS AND METHODS 
The design of this study was a historical cohort study based on the 
Continuous Morbidity Registration (CMR) database with a 35-year 
observation period. Details of the CMR database have been described 
elsewhere.16 Briefly, the CMR records since 1971 all new episodes of 
morbidity presented to general practitioners (GPs) in four general practices 
in the surroundings of Nijmegen, the Netherlands. The practices have a 
stable practice population of approximately 12,000 individuals.17 The 
turnover of patients in these general practices (because patients enter of 
leave the cohort) is low (< 5 %/year).17 All patients of the practices were 
informed of the use of the database for research and asked to provide 
written consent. Only anonymous information of the patients was used. 
Since only information already available in the CMR records was used, no 
approval of an internal review board was needed. The practice population 
is representative of the Dutch population in terms of age, gender, and social 
class.18 In the Netherlands, all inhabitants are listed with a general practice 
and receive all their medical care through this particular practice. As a 
consequence, a general practice has a complete overview of the patients’ 
medical history. 
 
Morbidity is registered by the GP at the time of diagnosis with a diagnosis-
oriented classification. Diagnoses made after referral to other specialists are 
included in the database, as is cause of death for deceased individuals. 
When the course of the illness or additional testing changes the diagnostic 
interpretation, the diagnosis is corrected in the system. If a diagnosis is 
modified, only the current diagnosis is available in the database.  
 
For each patient, sociodemographic information (age, sex, and 
socioeconomic status (SES), classified as low, middle, and high) and data 
on morbidity and mortality, if applicable, are available. SES is defined 
according to profession and education level based on the Dutch Standard 
Classification of Occupations, 1992.19 To classify morbidity, the Dutch 
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translation of the Royal College of General Practitioners’ E-book was 
introduced in 1971; at that time, this was the only general practice 
classification available.20 This classification has been maintained in the 
CMR database ever since, to preserve consistency of data over time. For the 
diagnostic categories, the criteria and definitions of the International 
Classification of Health Problems in Primary Care have been introduced in 
1984.21  According to the International Classification of Health Problems in 
Primary Care, depression should be diagnosed if at least three of the 
following symptoms occur: depressed mood; decrease in interest; suicidal 
thoughts; indecisiveness; feeling worthlessness/sense of guilt; 
insomnia/morning tiredness; anxiety/irritability; and psychomotor 
agitation. It has been demonstrated that for the large majority of patients in 
the database, their diagnosis is in agreement with the diagnostic criteria, 
like the diagnosis of patients with DM in reference to the World Health 
Organization criteria 22, and patients with a GP diagnosis of depression in 
reference to the Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition major depressive disorder criteria.23 No information on the 
validity of the diagnoses of COPD in the CMR database is available.  
 
We selected patients with DM type 1 or type 2 as a reference group of 
patients with another common chronic disease. Comorbidity was defined 
as the coexistence of one or more recorded chronic conditions with a 
prevalence > 2% in the CMR population in a patient with an index disease 
(COPD, DM). Long-term conditions included the following: hypertension, 
sinusitis, migraine, stomach ulcer, duodenum ulcer, malignant neoplasms, 
stroke, Parkinson disease, psychiatric disorders, arteriosclerosis, 
decompensation, cordis, asthma, myocardial infarction, angina pectoris, 
claudication intermittens, DM type 1 and type 2 (excluded as comorbidity 
for patients with DM), and arthritis (osteoarthritis, rheumatoid arthritis, 
ankylosing spondylitis and polyarthritis).  
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Selection of patients with COPD, DM, and control subjects without 
chronic conditions 
This study was based on all data of the CMR database until January 2006. 
All patients with COPD and DM diagnosed since 1971 with at least 1 
month of follow-up were considered for this study. They were identified in 
the CMR database. For COPD, this required a diagnostic code of chronic 
bronchitis (diagnostic code 2480) after the age of 40 years.20 For DM, this 
was diagnostic codes 0911 (type 1) or 0919 (type 2).20 Patients with 
depression diagnosed prior or at the same time the diagnoses of COPD or 
DM were assigned by the GP were excluded. DM patients with a diagnosis 
of nonatopic asthma after the age of 40 years or a diagnosis of COPD at any 
time during their life were also excluded. These patients were excluded to 
ensure that no patients with COPD who had been misclassified as having 
asthma would be included in the DM population. Moreover, patients were 
excluded if information on at least one of the covariates (i.e., SES, gender, 
age, or general practice) was missing.  
 
Patients with a COPD diagnosis were matched to control subjects drawn 
from the CMR cohort. These control subjects were free of any of the long-
term conditions listed above at the start of the observation period. We used 
‚greedy‛ propensity matching scoring, balancing the covariates SES, 
gender, age, and general practice in the propensity score model, with a 
variable number (1, 2 or 3) of control subjects for each patient with COPD.24 
In other words, for each patient with COPD, a maximum of three control 
subjects were selected, who had the same risk of depression based on the 
aforementioned covariates. For each control subject, a dummy ‚date of 
diagnosis‛ was defined that equaled the date of diagnosis of matched 
COPD patients. Thus, the observation time of matched control subjects 
started at the same point in time as the observation time for the matched 
COPD patients. In the propensity-matching procedure, control subjects 
with a diagnosis of depression before the dummy date could not be 
matched to a patient with COPD. Best matches were defined as those with 
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the highest digit match (0.00001) on the propensity score. The algorithm 
proceeded sequentially to matches with lower agreement in propensity 
score between COPD patients and control subjects. The lowest allowable 
digit match was 0.1. Control subjects could have chronic medical conditions 
developed during the observation period, with the exception that 
individuals with a diagnosis of nonatopic asthma after the age of 40 years 
or a diagnosis of COPD at any time during their life were excluded from 
the control group prior to the matching procedure. Again, these individuals 
were not included in the study to guarantee that no patients with COPD 
were included in the control group. 
 
Statistical analysis 
Characteristics of the COPD group were compared to the DM and control 
groups and analyzed using 2 tests and unpaired Student t test, i.e., rate of 
diagnosed with depression, time to newly diagnosed depression, gender, 
age, SES, comorbid diseases, observation time, and general practice.  
Cox proportional hazards analysis (i.e., survival analysis) was used to 
identify the risk of a first episode of GP-diagnosed depression in patients 
with COPD compared to the DM and control groups. Hazard ratios (HRs) 
are presented with 95% confidence intervals (CIs). An HR is broadly 
equivalent to relative risk, but takes the unequal observation time per 
subject into account. The following covariates were added to both models 
(i.e., COPD vs DM and COPD vs control subjects): age, gender, SES, general 
practice, and comorbidity. Comorbidity does not fulfill the proportional 
hazards assumptions and therefore we added comorbidity as a categorical 
time-dependent covariate in the model (i.e., months of follow-up with 
comorbidity compared to months of follow-up without comorbidity); p-
values used in all analyses were two-tailed; p ≤ 0.05 was considered 
statistically significant.  
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RESULTS 
The flowchart in Figure 4.1 summarizes the selection procedure of patients 
and control subjects in the study. Of the patients with COPD, 5.5% were 
excluded because depression had been diagnosed prior or at the same time 
of the diagnosis of COPD, or the date of first depression was unknown. For 
patients with DM, this was also 5.5%. 
 
Figure 4.1. Flowchart of the selection procedure of patients with COPD, DM, and control 
subjects without chronic conditions. Potential controls: no COPD ever, no 
morbidity at the time the patient registered at the general practice, and no 
morbidity with an unknown start date (e.g., the first registered episode of a 
disease is not coded as a new episode of an existing disease). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
38 excluded:  
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47 excluded:  
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prior or at the same time  
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prior or at the same time 
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Population in the Continuous Morbidity Registration (CMR) database 
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least one month  
follow-up in CMR 
(n = 1,085) 
COPD patients with at 
least one month  
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(n = 1,025) 
COPD patients 
(n = 1,076) 
DM patients with 
complete data 
(n = 978) 
COPD patients complete 
data 
(n =  1,038) 
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Table 4.1 shows the characteristics of the selected COPD, DM, and control 
groups. Patients with COPD had depression diagnosed almost twice as 
often by their GP, compared to patients with DM and control subjects 
without chronic conditions. The mean time to a first diagnosis of 
depression was 7.7 years (95%CI, 5.8 to 9.6 years) for patients with COPD. 
Time to a first depression did not significantly differ between COPD 
patients and DM patients (5.9 years; 95%CI, 4.0 to  7.7 years) or control 
subjects (7.3 years; 95%CI, 5.8 to 8.7 years).    
 
Table 4.1.  Characteristics of patients with COPD, patients with DM, and control subjects 
without chronic conditions.* 
 COPD 
(n=999) 
DM 
(n=978) 
controls 
(n=2.494) 
Cumulative incidence depression   61 (  6.1)   33c (  3.4)      94† (  3.8) 
Time to depression diagnosis, mo‡  92.2 (88.6)   70.3 (61.6)      87.4 (88.0) 
Gender 
Male 
Female 
 
681 
318 
 
(68.2) 
(31.8) 
 
443c 
535 
 
(45.3) 
(54.7)     
 
1,581† 
   913 
 
(63.4) 
(36.6) 
Age (dummy) diagnosis disease yr  62.7 (10.9)   61.8 (14.2)     60.7† (12.1) 
Presence of comorbid conditions 848 (84.9) 801 (81.9) 1,216† (48.4) 
Socio-economic status 
  Low 
  Middle 
  High 
 
547 
377 
  75 
 
(54.8) 
(37.7) 
(  7.5) 
 
497 
383 
  98 
 
(50.8) 
(39.2) 
(10.0) 
 
1,329 
   998 
   167 
 
(53.3) 
(40.0) 
(  6.7) 
Time in cohort until depression 
diagnosis or end of follow-up 
months 
  91 (40 – 159)   73 (40 – 131)      93 (40 – 168)  
* Data are presented as No. (%), mean and SD, or median (25th–75th percentile), †p ≤ 0.01 for difference with COPD 
group, ‡For COPD and DM: time from diagnosis of chronic condition (i.e., COPD or DM) until diagnosis of first 
depression. For control subjects: start of observation time until first diagnosis of depression. 
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 Table 4.2 shows that for a first diagnosis of depression in the COPD group 
compared to the DM group, and for a first diagnosis of depression in the 
COPD compared to control subjects, HRs are 1.80 (95% CI, 1.16 to 2.81) and 
1.68 (95% CI, 1.20 to 2.35), respectively. 
 
Table 4.2.  Cox proportional hazards regression models on depression of patients with 
COPD compared to patients with DM and control subjects without chronic 
conditions.* 
Variables COPD vs DM COPD vs controls 
Group 1.80† (1.16 - 2.81) 1.68† (1.20 – 2.35) 
Age 1.00 (0.98 - 1.01) 0.99 (0.97 – 1.01) 
Gender 
   Female vs. Males 
 
1.29 
 
(0.82 – 1.98) 
 
1.34 
 
(0.97 – 1.86) 
General practice‡ 
  2 vs others 
  3 vs others 
  4 vs others 
 
0.70 
0.56 
1.35 
 
(0.39 – 1.28) 
(0.30 – 1.06) 
(0.81 – 2.26) 
 
0.84 
0.71 
0.94 
 
(0.54 – 1.31) 
(0.46 – 1.11) 
(0.60 – 1.46) 
Socio-economic status¶ 
  Middle vs. others 
  High vs. others 
 
0.95 
1.21 
 
(0.61 – 1.48) 
(0.57 – 2.58) 
 
1.22 
1.54 
 
(0.86 – 1.72) 
(0.85 – 2.80) 
Months with comorbidity vs months with  
no comorbidity (time depending covariate) 
0.98 (0.64 – 1.52) 1.10 (0.77 – 1.57) 
* Data are presented as HR (95% CI),
 †
p ≤ 0.01, ‡ Reference group: general practice 1, 
¶ 
Reference group: low SES. 
  
Figure 4.2 visualizes the survival curve (time until first episode of 
depression) in patients with COPD and control subjects. Figure 4.3 shows 
the survival curve for patients with COPD and patients with DM. The 
figures show that patients with COPD have a higher probability of a first 
episode of depression at any time during the observation time compared to 
patients with DM and control subjects. 
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Figure 4.2. Survival curve (time until first episode of depression) in patients with COPD and 
control subjects.  
 
 
Figure 4.3.Survival curve for patients with COPD and patients with DM.  
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DISCUSSION 
The objective of this study was to determine the incidence of GP-diagnosed 
initial episodes of depression in patients with COPD, and to compare the 
risk of depression with patients with DM and with control subjects without 
chronic conditions. In total, 5.5% of the COPD population and DM group 
were not selected for this study because depression had been diagnosed at 
the same time or prior to the diagnosis of COPD or DM. Our study showed 
that the risk for a depression was approximately 1.7- to 1.8-times higher for 
patients with COPD compared to DM patients, as well as for control 
subjects without chronic conditions. 
 
The prevalence of depression in patients with COPD has been studied 
before. Reported prevalence rates range from 6 to 59%.5-12 Although 
prevalence rates provide information on the cross-sectional association 
between COPD and depression, it does not provide crucial information on 
the temporal relation between COPD and depression. In other words, it 
remains unclear whether or not COPD causes a higher risk of depression.  
Only two longitudinal studies on depression in patients with various 
medical conditions have been published that also concerned patients with 
COPD 4 or ‚chronic lung disease‛ (asthma and COPD).25 Both studies 
collected information on depression based on self-reported questionnaire 
scores like the Centre for Epidemiologic Studies Depression Scale.4,25  Using 
such questionnaires to determine depressive disorders can result in higher 
scores based on the nature of the underlying chronic disease and is not the 
same as a clinically verified event.6 Physical symptoms (fatigue, 
sleeplessness/insomnia, poor appetite) are an integral part of depression 
questionnaires, but it is not possible to distinguish between ‚depression-
generated‛ and ‚physical condition-generated‛ symptoms. This may result 
in overreporting of depression. Our study was based on a clinical diagnosis 
of depression by GPs, in a research practices’ database with high diagnostic 
specificity compared to the Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition criteria.23 This high specificity had also been 
found in other studies.26 In our study, working from a clinical diagnosis 
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made it possible to avoid the limitations depression questionnaires have in 
patients with chronic conditions. However, it is likely that depression is 
underrepresented in general practice because not all patients seek 
treatment when depressed or the GP may record it other than depression. 
This particularly applies to patients with less severe depression. As a 
consequence, our findings might reflect more serious or chronic episodes of 
depression in patients with COPD. Despite the differences between our 
study and previous studies, the cumulative incidence rate of depression in 
our study was more or less comparable with the findings reported by 
Patten (i.e., 6.7%).4 Bisschop et al. do not report on the incidence of 
depression.25  
 
We found that the mean time elapsed between the date of diagnosis of 
COPD and the first episode of depression was 7.6 years. Unfortunately, this 
could not be compared with these two aforementioned studies because 
these studies had follow-up periods of 2 years and 6 years, respectively, 
and did not use longitudinal data-collection like our study.4,25 
 
The CMR database with its longitudinal design is an important strength of 
our study because we were able to investigate the temporal direction in 
which COPD and depression are related. The CMR database consists of 
information that is systematically recorded by GPs in daily routine care. 
Therefore, it enabled us to restrict the study sample to subjects who were 
free of diagnosed depression until the start of the observation period. 
Survival analysis adjusts for censored data, so no eligible subjects dropped 
out because of death or leaving the CMR practice, which resulted in a 
sufficiently large sample of COPD patients and sufficiently large reference 
groups. A limitation of the CMR database is the absence of objective data 
on the lung function of the patients were diagnosed with COPD and 
information on smoking status.    
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There are many mechanisms that could be responsible for the higher risk of 
depression in patients with COPD. First of all, patients with chronic 
respiratory disease have worse physical functioning than patients with 
other chronic diseases, and it has been shown that the level of functional 
impairment itself is related to a higher rate of depression. 27,28, However, in 
one study the physical limitations did not seem to play a mediating role on 
the relation between chronic lung disease and depression.25 The lack of 
control on the course of the disease experienced by the patient could be a 
second mechanism that results in depressive symptoms.25 Moreover, the 
hypoxic nature of severe COPD can result in an organic depression, and 
dyspnea can cause much distress and higher depression rates in patients 
with COPD.10 In addition, COPD is a disease that primarily occurs in 
patients with advanced age, and low SES, and the nature of the disease can 
result in social isolation, feeling useless, and immobility, all factors 
associated with depression.29  
Comorbidity is a well-established phenomenon that was found in 85% of 
the patients with COPD in this study but did not result in higher risk for 
depression in patients with COPD compared to healthy control subjects 
and DM patients. This result is comparable with the findings of Manen et 
al., who examined the relationship between various variables and the risk 
for depression in COPD patients and found that comorbidity was no 
significant determinant for the level of depression in patients with COPD. 
It might be that the overlap between symptoms of depression and somatic 
diseases complicates the recognition of depression.30 This finding warrants 
further investigation. We included psychiatric diseases in the list of 
comorbid conditions. The HR for a first episode of diagnosed depression 
for patients with COPD compared to DM and healthy control subjects were 
calculated based on the same Cox proportional hazard model with the 
exception of psychiatric comorbidity. Only negligible differences with the 
results in Table 4.2 were found. Therefore, the psychiatric comorbidity did 
not have an important effect on our findings. 
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Some interventions for patients with COPD, like comprehensive 
pulmonary rehabilitation, appear to result in a decline of depressive 
symptoms.31 Moreover, treatment and recovery for depression are difficult 
but achievable.32 A stepped-care approach for the treatment of depression 
in a primary care population was found to be effective and might be 
suitable for patients with COPD as well.33 Therefore, the negative effect that 
a depressive disorder can have on the life and health of patients with 
COPD may be prevented or reduced. Physicians need to be aware of the 
higher risk of depression in COPD patients to attain early detection and 
start early treatment. 
In conclusion, we found that patients with COPD have a higher risk of 
physician-diagnosed depression than patients with DM and control 
subjects without relevant chronic conditions. Therefore, a temporal relation 
between COPD and diagnosis of depression seems to exist. Moreover, it 
seems that the increased risk of depression is not the result from having a 
chronic disease in general but is specific for COPD. For daily care, these 
results imply that physicians involved in the management of COPD need to 
be aware of the increased risk of depression in these patients. 
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ranssen et al. reported potential links between obesity and chronic 
obstructive pulmonary disease (COPD).1 In their review, the authors 
use obesity prevalence estimates for COPD patient populations from 
only two studies with a relatively small sample sizes.2,3 Therefore, in our 
view whether or not obesity is actually more prevalent in patients with 
COPD is still a matter of debate. Moreover, the current evidence of a 
possible association between obesity and a worse COPD disease state is 
inconclusive. This information is crucial before considering any potential 
underlying mechanisms of this presumed association. 
 
In order to contribute to the discussion on the role of obesity in COPD, we 
analysed data from a Dutch regional primary care diagnostic centre to 
address these questions. The procedures and database have been described 
elsewhere.4 In short, our database contains spirometry tests of patients 
referred by general practitioners. Also information on body mass index 
(BMI), smoking habits, exacerbation rate, and level of dyspnoea (Medical 
Research Council (MRC) score) are collected during all visits.4 For the 
current analysis, we used information from the most recent spirometric 
tests from all current and former smokers with respiratory symptoms aged 
>40 years and a postbronchodilator forced expiratory volume in 1 s (FEV1)/ 
forced vital capacity (FVC) of < 0.70. BMI (kg/m2) was categorised as low 
weight (BMI ≤ 21), normal weight (21 < BMI < 25), overweight (25 ≤ BMI < 
30), and obesity (BMI ≥ 30). Obese patients were compared with normal 
and overweight patients in terms of postbronchodilator FEV1% predicted, 
FVC and MRC scores. The associations between obesity and these 
outcomes were analysed with linear regression and ordinal regression. The 
models were corrected for age, gender and current smoking habit. 
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Table 5.1 shows the characteristics of the study population (n=1,761) by 
BMI category. Overall, 15.1% of the study subjects were obese. FVC was 
250 ml lower in obese patients compared with patients with normal weight 
and overweight (p<0.01). We found no association between obesity and 
post FEV1% predicted, but obesity was associated with higher MRC scores 
(odds ratio (OR) 2.05, 95%CI,1.67 to 2.52).  
 
Table 5. 1. Characteristics of the study population by body mass index (BMI) category.  
 Low weight 
BMI ≤ 21 
(n=222) 
Normal weight 
BMI 21.01-24.99 
(n = 583) 
Overweight 
BMI 25 - 29.99 
(n = 690) 
Obesity 
BMI ≥ 30 
(n = 266) 
Age*     60.3† (11.2)     62.2 (10.7)     63.9 (10.3)     63.6 (10.0) 
Gender 
(male) 
  104 (46.8)   363 (62.3)   497 (72.0)   168 (63.2) 
Current 
smoker 
  154 (69.4)   331 (56.8)   289 (41.9)   111 (41.7) 
GOLD stages         
- I     32 (14.4)     89 (15.3)     91 (13.2)     22 (13.3) 
- II   100 (45.0)   362 (62.1)   440 (63.8)   187 (70.3) 
- III or IV     90 (40.6)   132 (22.6)   159 (23.1)     57 (21.5) 
MRC score         
- 0     55 (24.8)   211 (36.2)   215 (31.2)     46 (17.3) 
- 1     92 (41.4)   238 (40.8)   277 (40.1)   114 (42.9) 
- 2 - 4     75 (33.8)   134 (23.0)   198 (28.8)   106 (39.8) 
Postbronchodilator lung function     
FEV1% pred*     56.5 (18.2)     63.0 (16.8)     62.7 (16.2)     61.1 (13.4) 
FVC (L)*       3.2       (0.96)       3.4 (1.00)       3.4 (1.00)       3.1 (0.92) 
FEV1/FVC *       0.54 (0.11)     0.57 (0.10)       0.59 (0.09)       0.62 (0.07) 
Figures are number and percentage unless stated otherwise, FEV1: forced expiratory volume in 1 s, FVC: forced vital 
capacity, GOLD: Global Initiative for Chronic Obstructive Lung Disease, MRC: Medical Research Council, * mean (SD), 
† All differences between groups were significant (p < 0.01).  
 
The prevalence of obesity in our population was lower compared with the 
study by Steuten et al. (i.e., 18%), but still slightly higher compared with the 
general Dutch population aged ≥ 45.5 Only the FVC was reduced in the 
obese COPD patients.  
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This is an important observation, as this could result in under-
representation of COPD in obese individuals when the main GOLD (Global 
Initiative for Chronic Obstructive Lung Disease) criterion (i.e., 
FEV1/FVC<0.70) is applied to demonstrate airflow obstruction.  
 
Although our findings indicate that the prevalence of obesity in patients 
with COPD is only slightly higher compared with that of the general 
population, obesity is a prevalent problem in patients with COPD 
associated with a higher level of dyspnoea. Therefore, we ask for more 
attention to be paid to obesity in patients with COPD, in both research and 
patient care. Our efforts should focus not only on research into potential 
links between obesity and COPD, but also on effective ways to prevent and 
treat obesity in COPD patients, which may require a different approach 
from that in healthy subjects.  
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ABSTRACT 
Objective: To investigate the long-term effectiveness of a general practice 
monitoring system with respiratory expert recommendations for general 
practitioners’ management of patients with chronic obstructive pulmonary 
disease (COPD), compared with usual care. 
Design, settings and participants: A multicentre randomised controlled 
trial of patients with COPD, clustered by general practices; 200 participants 
were recruited to maintain at least 75 participants per group for analysis. 
The trial took place from July 2005 to February 2008 in the south-western 
region of the Netherlands. 
Intervention: Ongoing half-yearly monitoring of COPD patients with 
respiratory expert recommendations for the GP was compared with usual 
care. 
Main outcome measures: Primary outcome — Chronic Respiratory 
Questionnaire (CRQ) score; secondary outcomes — CRQ domain scores, 
generic health-related quality of life (Short-Form 12 and EuroQol-5D), 
breathlessness (Modified Medical Research Council score), exacerbations, 
and decline in forced expiratory volume in 1 second. A detailed process 
evaluation was performed along with the trial. 
Results: Data from 170 participants were analysed. Based on repeated 
measurement analyses, the additional gain in CRQ score during follow-up 
was 0.004 points for monitoring compared with usual care (95% CI, −0.172 
to 0.180). Also, no important differences between monitoring and the usual 
care group were found for secondary outcomes. Half the monitoring visits 
resulted in disease management recommendations by a respiratory expert, 
and 46% of these recommendations were implemented by the GPs. Patient 
adherence to lifestyle recommendations was low. 
Conclusion: An expert-supported monitoring system for patients with 
COPD was not clinically effective. As patients had a pre-existing entry in 
the monitoring system, the population may be well regulated, with 
reduced room for improvement. 
Trial registration:www.clinicaltrials.gov NCT00542061. 
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apid changes in general practice have increased possibilities to 
diagnose and manage chronic diseases such as chronic obstructive 
pulmonary disease (COPD). Several national and international 
guidelines for COPD are available1-4 to help general practitioners with this. 
‚Monitoring‛, or regular surveillance of patients’ health status, is a 
cornerstone of COPD management.5 Input of specialist knowledge into 
monitoring enables comparison of the process and outcome of care with 
evidence-based guidelines. It can also alert GPs to areas in which 
individual patient care falls short, and introduce explicit recommendations 
for management.  
Our group has demonstrated the effectiveness of expert-supported 
monitoring on the outcome of diabetes care in general practice.6 COPD 
management places a substantial demand on medical resources,7,8 and 
patient adherence is important to the success of treatment.9 Any expert-
supported respiratory monitoring system depends on the cooperation of 
various groups (i.e., GPs, specialists and patients), contains interacting 
components, and is, therefore, a complex intervention.10  
We aimed to investigate the long-term effectiveness of a primary care 
monitoring system with respiratory expert recommendations for GPs’ 
management of patients with COPD, compared with usual care. We 
performed a detailed process evaluation along with the trial; elements of 
this evaluation are also reported here. 
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METHODS 
Study design 
We conducted a multicentre parallel group study with a 24-month patient 
follow-up (www.clinicaltrials.gov NCT00542061). The trial took place from 
July 2005 to February 2008. We allocated general practices to intervention 
(i.e., respiratory expert-supported COPD monitoring system) or usual care. 
All participants at each general practice were allocated to the same 
treatment group (cluster randomised design). We hypothesised that 
ongoing half-yearly monitoring with respiratory expert recommendations 
of patients with COPD would result in a clinically relevant gain in quality 
of life compared with usual care.  
The study protocol was approved by the medical ethics committee of the 
Arnhem Nijmegen region in the Netherlands. All patients gave written 
informed consent.  
 
Participants and sample size calculation  
We selected and invited study participants based on patient records 
already available at a regional diagnostic centre (RDC) in the south-western 
region of the Netherlands.  
Inclusion criteria were:   
 patient diagnosed with COPD or asthma with persistent airflow 
obstruction, as confirmed with the patient’s most recent 
spirometry (forced expiratory volume in 1 second (FEV1)/forced 
vital capacity (FVC) < 70%, or postbronchodilator FEV1 < 80% 
predicted and ≥ 9% reversibility);11,12  
 the patient’s lung function data from the previous year were 
available at the general practice diagnostic centre; and  
 patient aged at least 25 years. 
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Exclusion criteria were: 
 patient treated by a chest physician; 
 patient participating in another respiratory intervention study; 
 GP considered it detrimental to the patient to participate in the 
study; 
 patient had any serious other nonpulmonary diseases (or disease 
stages) or pulmonary diseases (eg, sarcoidosis, lung cancer, lung 
fibrosis); or 
 patient could not read. 
 
GPs at practices who had referred more than six patients to the RDC were 
contacted and asked to participate. We used computerised minimisation to 
allocate practices to the monitoring and usual care groups13,14 while 
stratifying for: 
 group versus solo practice; 
 practice nurse employed versus no practice nurse employed; and 
 ≤10 versus > 10 patients fulfilling the study inclusion criteria. 
 
A multilevel power calculation (i.e., correction for clustering of subjects 
within general practices) was based on the mean difference in change in 
Chronic Respiratory Questionnaire (CRQ) score between monitoring and 
usual care. A difference of 0.5 points is generally accepted as a minimum 
important clinical difference for the CRQ score.15 We initially aimed to 
recruit 100 participants per group based on the following assumptions: an 
intracluster correlation coefficient of 0.04; α= 0.05; 1-β = 0.80; and a dropout 
rate of 25%. 
 
Blinding 
In their study information letters, GPs and patients were informed that 
patients were invited for an unspecified number of visits to the RDC. GPs 
were informed that participation could imply that the outcome of their 
patients’ visits would not be forwarded to them during the study as it had 
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been previously. After minimisation, GPs received specific research 
information for their practice. The respiratory experts involved and the 
lung function technicians who performed the spirometric tests and 
collected medical information were not aware of patients’ participation and 
allocation. 
 
Intervention 
The expert-supported COPD monitoring system had been in use in the 
RDC since 1995, and comprised several steps.  
Step A. Patients with COPD were invited to the RDC for monitoring visits 
every 6 months. Pre- and post- (after inhaling 400 μg salbutamol) 
bronchodilator FEV1 and FVC were measured at each visit with a 
SpiroPerfect spirometer (WelchAllyn, Delft, The Netherlands) by certified 
lung function technicians. Body mass index was assessed,and information 
on respiratory symptoms, exacerbations, smoking and medication use in 
the previous 6 months was collected in a standardised way. 
Step B. Information from the monitoring visit and previous visits was sent 
to a respiratory expert (chest physician or GP with special respiratory 
interest). The respiratory experts gave recommendations regarding 
treatment, additional diagnostic tests and referrals to other disciplines, 
based on national clinical practice guidelines for COPD and asthma.11,12 
Experts’ interpretation based on spirometry results and written information 
has been shown to be valid.16  
Step C. Written feedback was sent to the patient’s GP. The patient was 
instructed to visit the GP 2 weeks after the monitoring visit to discuss the 
outcome. During these visits, the expert recommendations could be 
implemented by the GP (eg, checking inhalation technique) or 
recommended to the patient. Half-yearly visits from a nurse consultant to 
the practice to support GPs in implementing the recommendations were an 
integral part of the expert-supported monitoring system. 
Step D. Ultimately, the patient should implement the recommendations 
made (eg, quit smoking, increase exercise).  
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Usual care 
We invited participants from the usual care group for spirometry at the 
beginning and at the end of the trial. No recommendations or feedback 
were given, and no nurse consultant practice visits were scheduled during 
the study period. 
 
Outcomes and process evaluation 
Participants completed questionnaires at baseline, at 1 year, and at the end 
of the study. The primary study outcome was the CRQ score.17 Secondary 
outcomes were: CRQ domain scores; generic health-related quality of life 
(physical and mental domains of the Short-Form 12 [SF-12] and the Euro-
Qol-5D);18-20 breathlessness according to level of exertion (Modified Medical 
Research Council [MMRC] score,2 dichotomised as 0–1 and 2–4); occurrence 
rate of selfreported exacerbations; and annual FEV1 decline. 
For the process evaluation, the respiratory experts’ database was examined 
to collect data on their recommendations. The nurse consultant collected 
data on GPs’ implementation of recommendations. Patient questionnaires 
comprised questions about disease management. At the end of the study, 
the nurse consultant collected information on disease management from 
GPs in the usual care group. 
 
Statistical analysis 
Baseline characteristics for the participants in each group were compared 
using unpaired t tests, χ2 tests, and Mann–Whitney U tests, depending on 
the type of variable and normality of distribution. Multilevel repeated 
measurement regression analysis was used to model the effect of 
monitoring on CRQ overall score, CRQ domain scores, SF-12 scores, 
EuroQol-5D scores, FEV1 decline, and dichotomised MMRC scores. We 
used a PROC MIXED procedure in SAS statistical software (SAS Institute, 
Cary, NC, USA), with general practice as the random coefficient and 
compound symmetry correlation structure. Multilevel logistic regression 
analysis was used to analyse effects on exacerbations. All models were 
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corrected for sex, age, socioeconomic status, baseline cigarette smoking 
status, reversibility, exacerbations at baseline, use of inhaled 
corticosteroids, use of long-acting bronchodilators, and postbronchodilator 
FEV1% of the predicted value. Participants were included in the analysis if 
they participated in the study(intention-to-treat analysis). 
   
 
 
Figure 6.1.  Flow chart of practice and participant recruitment, inclusion and drop-out 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*according to the patient’s general practitioner,  † analyses were based on intention-to-treat principle.  
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Practice allocation 
by minimisation 
 
Analysis 
 
10 excluded from analysis: first 
questionnaire filled out too late (6); 
questionnaire missing (2); too many 
missing answers (2)  
9 excluded from analysis: 
 first questionnaire filled out too late (4); 
questionnaire missing (3); too many 
missing answers (2) 
Follow-up 
completed 
 
Baseline visit 
 
56 general practices invited 
34 general practices participated 
16 practices allocated 
to intervention 
18 practices allocated 
to usual care 
22 practices refused to participate 
185  patients 219 patients 
132 eligible patients 154 eligible patients 
53 excluded: treated by chest 
physician (24); other disease (2);too 
old* (4); other reasons (23) 
65 Excluded: treated by chest 
physician (34); other disease (4); too old* 
(2); other reasons (25) 
101 participants 112 participants 
31 refused: personal reasons (8); 
lack of time (1); no transportation (2); 
no interest (2); other reasons (4); no 
explanation (4); no response (10) 
42 Refused: personal reasons (10); 
lack of time (5); no interest (1); other 
reasons (5); no explanation (6); no 
response (15)d 
82 participants 86 participants 
 
92 participants 97 participants 
 
9 did not enter study: treated by 
chest physician (2); 
severe comorbidity (2); personal 
reasons (4); other reasons (1) 
15 Did not enter study: treated by 
chest physician (1); personal reasons (1); 
did not attend first lung function test (4); 
died (1); general practice stopped (5); 
other reasons (3)f 
10 dropouts: lack of time (1); age 
(1); comorbidity (4); no longer 
interested (1); referred to chest 
physician (2); missing (1) 
 4 discontinued intervention 
11 dropouts: died (4); lack of time (1); 
comorbidity (2); no longer inte-rested 
(2); personal circumstances (2) 
88 participants† 
 
82 participants† 
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RESULTS 
Study population 
Figure 6.1 shows the process of practice and patient recruitment and 
follow-up. Thirty-four general practices participated. From these, 261 of 286 
eligible patients (91%) responded to the invitation, and 213 (74%) were 
willing to participate. No significant differences between participants and 
non-participants with regard to sociodemographic characteristics, 
medication use, and spirometric indices were found. Twenty-four patients 
did not enter the study, and 19 patients were excluded from analyses. Data 
from 170 participants were used for the analyses. Table 6.1 shows the 
baseline characteristics of both groups.  
Table 6.1. Baseline characteristics of participants.  
 
Monitoring group (n=82) Usual Care group (n=88) 
Age in years, mean (SD)  62 (10.5) 64 (10.5) 
Males 56* 47 
Post-BD FEV
1 
% of predicted  70†‡, 77 
Post-BD FEV
1
/FVC 61 * ‡, 65 
Short-acting BDs 33‡ 26 
Long-acting BDs 52‡ 58 
ICS 59‡ 65 
Smoking       Yes  53† 40 
                        No   6 18 
Former smoker  23 30 
Pack-years, mean (SD) 27.5 (21.8)* 20.7 (18.1) 
MMRC score 0  11‡ 16 
                        1  36 30 
                        2   26 35 
                        3    6   5 
                        4-5    2   2 
≥ exacerbations in past year 16§ 17 
BD: bronchodilator, FEV1: forced expiratory volume in 1 second, FVC: forced vital capacity, ICS: inhaled 
corticosteroids, MMRC: Modified Medical Research Council, *Difference between monitoring group and usual care 
group significant; P <0.05, †Difference between monitoring group and usual care group significant; P <0.01, ‡One 
missing value, §Two missing values. 
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The study was originally designed to evaluate monitoring of patients with 
COPD and asthma with a chronic airflow obstruction. However, after the 
recruitment phase we found that almost all of the patients fulfilled the 
criteria for COPD (i.e., FEV1/FVC < 70% postbronchodilator); therefore, we 
decided to focus on COPD. 
 
Clinical effectiveness of the expert-supported monitoring system. 
Figure 6.2 shows the mean overall CRQ scores in the monitoring and usual 
care groups. Based on repeated measurement analyses, the additional gain 
in CRQ score during follow-up was 0.004 points for monitoring compared 
with usual care (95% CI, - 0.172 to 0.180). Table 6.2 summarises the results 
for the secondary outcomes. No significant differences between the 
monitoring and usual care groups were observed other than CRQ domain 
mastery. 
Figure 6.2. Mean CRQ score (95% CI) of expert-supported COPD monitoring compared with 
usual care at baseline and at 1 and 2 years. 
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Table 6.2.  Effects of expert-supported chronic obstructive pulmonary disease monitoring compared with usual care on outcomes of 
respiratory health and quality of life. 
A) Mean (95% CI) at baseline, change (95% CI) at follow-up, and difference between groups (95% CI) for continuous variables 
 
Monitoring group Usual care group   
 Baseline 
 
(n=82) 
Change at two-year 
follow-up 
(n=76) 
Baseline 
 
(n=88) 
Change at two-year 
follow-up 
(n=80) 
Adjusted incremental 
2-year change* 
MICD 
Overall CRQ score 5.1 (4.9-5.3)   0.12 (-0.02-0.26) 5.3 (5.2-5.5)   0.12 ( 0.00-0.24)  0.5 
   CRQ domain dyspnea 4.9 (4.6-5.3)†   0.30 ( 0.10-0.50) 5.4 (5.1-5.7)‡   0.29 ( 0.07-0.50)‡   0.018 (-0.24-0.27) 0.5 
   CRQ domain fatigue 4.9 (4.7-5.2) - 0.09 (-0.32-0.13)  5.1 (4.9-5.3)   0.13 (-0.09-0.34) -0.236 (-0.54–0.07) 0.5 
   CRQ domain emotions 5.4 (5.2-5.6)   0.08 (-0.11-0.27) 5.5 (5.3-5.7)   0.09 (-0.06-0.24) -0.005 (-0.26–0.25) 0.5 
   CRQ domain mastery 4.8 (4.7-5.0)§   0.17 ( 0.02-0.33) 5.1 (4.9-5.3) - 0.03 (-0.16-0.11)  0.223† (0.02–0.42) 0.5 
SF12 physical scale 44.5 (43.0-46.1)¶ - 1.44 (-2.98-0.10) ‡ 43.8 (42.3-45.4)** - 0.16 (-1.73-1.42)†† -1.323 (-3.40-0.75) 3-5 
SF12 mental scale 52.2 (50.2-54.1)¶   0.09 (-1.85-2.03) ‡ 52.7 (51.1-54.2)** - 0.23 (-1.94-1.49)††  0.324 (-2.24-2.89) 3-5 
EQ5D score 0.89 (0.86-0.92) - 0.02 (-0.05-0.01) 0.87 (0.84-0.89)   0.00 (-0.03-0.03) -0.022 (-0.07-0.02) 0.07 
B) Frequency (no. (%)) of categorical variables at baseline and follow-up, and odds ratios 
 
Monitoring group Usual care group   
 
Baseline 
(n=82) 
2-year follow-up 
(n=76) 
Baseline 
(n=88) 
2-year follow-up 
(n=80) 
Odds ratio  
MMRC score ≥ 2   8 (  9.9) ¶   12 (15.8)   7 (  8.0) 10 (12.7) ¶ 1.05 (0.34-3.24)  
≥ 1 exacerbations in 
previous year 
16 (20.0)‡   12 (15.8) 17 (19.8)‡ 10 (12.7) ¶ 0.87‡‡ (0.38-2.11)  
CRQ: Chronic Respiratory Questionnaire, SF-12: Short-Form 12, MICD: minimum important clinical difference, MMRC: Modified Medical Research Council, * monitoring versus usual 
care based on multilevel repeated measurement analysis corrected for sex, age, socioeconomic status, smoking status at baseline, reversibility, exacerbations at baseline, use of inhaled 
corticosteroids, use of long-acting bronchodilators, and postbronchodilator forced expiratory volume in 1 second % of predicted value, †difference between monitoring and usual care 
is significant; P<0.05, ‡ two missing values, § difference between monitoring and usual care is significant; P<0.01, ¶ one missing value, ** three missing values, †† seven missing values., ‡‡ 
monitoring versus usual care based on multilevel logistic regression analysis, corrected for covariates. 
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Process evaluation 
A total of 292 visits took place among the monitoring group participants. 
Fifty-eight participants attended all four planned monitoring visits at the 
RDC (71%). Fifteen patients (18%) attended three, six patients attended 
two, and three patients attended one planned visit. In total, respiratory 
experts gave 290 recommendations (Table 6.3). Smoking cessation was the 
most frequent recommendation (28% of all recommendations), and inhaler 
technique training and assessment of compliance with medical treatment 
were also recommended regularly. In 146 monitoring visits (50%), the 
respiratory experts did not consider any modification in disease 
management necessary.  
 
Table 6.3. Number of times a respiratory expert recommended each disease management 
change, and general practitioner adherence to recommendations overall and in 
practices with and without a practice nurse. 
   GPs’ adherence 
Recommendations Expert 
recommend-
ations 
Recommend-
ations 
evaluated* 
Overall Practices 
with 
nurse† 
Practices 
without 
nurse† 
Cease smoking   82   78   44 25/47 19/31 
Optimise physical condition   21   20     6   2/5   4/15 
Avoid allergens and triggers     4     4     3   1/1   2/3 
Check inhaler technique    47   45   21 15/23   6/22 
Check treatment compliance     49   46   29 18/25 11/21 
Reduce bodyweight     4     3     1   1/2   0/1 
Introduce ICS   15   14     5   2/7   3/7 
Increase ICS dosage     6     6     3   1/2   2/4 
Reduce dosage or cease ICS   10   10     6   6/10   0/0 
Introduce short-acting BD     1     1     1   1/1   0/0 
Introduce  long-acting BD   10     8     0   0/4   0/4 
Additional diagnostic 
procedures 
    3      3     0   0/2   0/1 
Chest X-ray   14   13     3   1/8   2/5 
Refer to chest physician   24   23     3   1/9   2/14 
Total 290 274 125 74/146‡ 51/128 
Adherence: GP attempted to implement recommendation, BD: bronchodilator, ICS: inhaled corticosteroids, * eleven 
recommendations were not discussed by GPs and three GPs’ responses were missing, †no. of GPs adhering to 
recommendation/no. of recommendations evaluated in each type of practice, ‡ difference between practices with and 
without practice nurses is significant; P <0.05 (χ2 test). 
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For 73 patients (89%), the GPs received at least one recommendation to 
change disease management. Information about 274 of the 290 
recommendations could be collected (Table 6.3). According to GPs, they 
attempted to implement 125 (46%) of the 274 recommendations. In 
practices with a practice nurse, the implementation rate of 
recommendations was higher than in practices without a practice nurse (P 
< 0.05); in particular, inhaler technique training and checking medication 
compliance were implemented more frequently (Table 6.3). The main 
reason why recommendations were not implemented was because patients 
did not visit the practice after their monitoring visit at the RDC. On 45 
occasions, patients did not visit the GP after a monitoring visit that had 
resulted in at least one recommendation. Changes in disease management 
are shown in Table 6.4. In general, only minor changes in disease 
management were achieved in the monitoring group, and these changes 
were comparable to usual care. 
 
  
 Evaluation of a COPD monitoring system 
   
109 
Table 6.4 Chronic obstructive pulmonary disease management by general practitioners 
and patients in the second year of the study. 
BD: bronchodilator, ICS: inhaled corticosteroids, na: not applicable, recommendations: by GPs, recommendations in 
monitoring group: these were based on expert recommendation or own initiative, * according to the patient, † 
implementation of recommendations by the patient, ‡ patient stopped smoking according to the last questionnaire and 
medical information of the last visit to the regional diagnostic centre, § ±3 kg bodyweight change according to 
measurement during lung function visits, ¶ information on exercise tolerance was not collected, ** according to GPs’ 
electronically recorded information (nine missing values in monitoring group; 10 missing values in usual care group).  
 Monitoring group (n = 82) Usual Care group (n = 86) 
 Recommend- 
Ations*  
Implement- 
ation† 
Recommend- 
ations* 
Implement- 
ation† 
Cease smoking  14   3 13   0  
Increase bodyweight    1   1§  0  -  
Reduce bodyweight  16   0§  12   0§  
Increase physical exercise  13 na¶    7 na¶ 
Check treatment compliance  -  22* -  20* 
Check inhaler technique -  14* -  18*  
Introduce/increase ICS dosage** -    4 -    5 
Reduce dosage or cease ICS** -   4 -   3 
Introduce short-acting BD** -   7 -   5 
Introduce  long-acting BD** - 11 -   8 
Chest X-ray** -   6 -   5 
Refer to a Lung Physician   9   9*†   6   6* 
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DISCUSSION 
We did not find a clinical benefit for patients who received ongoing care 
according to a well structured respiratory expert-supported COPD 
monitoring system compared with usual care by GPs. The adherence of 
patients to the monitoring visits was good. In half the cases, the respiratory 
experts felt that disease management could be improved, and almost half 
the recommendations by respiratory experts were implemented by GPs. 
Non-adherence of patients to visiting the GPs and making lifestyle changes, 
and the low adherence of GPs to some recommendations (eg, referral to 
chest physician, chest x-ray) were the main barriers to the implementation 
of the expert recommendations. 
 
All patients who were invited had previously visited the diagnostic centre 
for at least one lung function assessment. It may be argued that we did not 
find effects in the study because we studied the effect of monitoring on a 
population with pre-existing entry into the monitoring system, rather than 
the effect of monitoring on a newly diagnosed population. Essentially, we 
compared health effects in a control group that had discontinued 
monitoring with those in the treatment group that had continued and 
intensified monitoring. This might have resulted in less ‚room for 
improvement‛ compared with a ‚naïve‛ population of COPD patients. The 
inclusion of newly diagnosed patients could have resulted in better clinical 
results. However, our aim was to determine the long-term usefulness of 
disease monitoring. The evaluated monitoring system has already been 
implemented on a large scale in the Netherlands, and after patients with 
COPD have entered the service, they are usually followed for many years. 
Our results indicate that keeping an expert-supported monitoring system 
in place for years appears not to benefit COPD patients.  
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Moreover, it was not possible to blind GPs and patients in this study, as 
information on process and outcome was reported by them. Patients who 
are aware of their treatment assignment may expect certain benefits that 
may influence the outcome, especially when the outcome is influenced by 
individual opinions, as with quality of life. However, monitoring group 
participants reported no higher health-related quality-of-life scores 
compared with usual care group participants. 
 
As far as we are aware, this is the first time the effectiveness of a COPD 
expert-supported monitoring system has been evaluated. However, other 
programs that focus on monitoring, like an integrated COPD and/or 
asthma management care model, a GP feedback system, and monitoring of 
health-related quality of life of patients with asthma and COPD, also did 
not result in clinical benefits, although some improvements in patient 
satisfaction and process outcomes were found.21-24 Other monitoring 
systems, such as monitoring of COPD by respiratory nurses in a general 
practice or a ‚patient-tailored‛ monitoring system, should be explored. 
Moreover, more information on the initial effect of the expert-supported 
monitoring system in newly diagnosed patients is needed (i.e., including 
patients who were not already known to the RDC). It may be that the 
support system is able to put COPD management on track, and that after 
this initial support, GPs are sufficiently equipped to manage the patients.  
 
The question remains whether the lack of effect was due to implementation 
failure — and therefore the system has the potential to be effective if 
implementation could be improved — or was a result of an ineffective 
intervention.10 Many participants failed to visit the GP, although the 
adherence rate to GP visits was significantly higher in general practices that 
invited patients for regular visits. Moreover, the presence of a practice 
nurse resulted in higher implementation levels. Therefore, implementation 
can be improved, but it is not possible to fully prevent dilution of effects in 
the process of monitoring and feedback. Options to reduce disease 
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progression are limited in COPD.25,26 Moreover, little evidence exists that 
chronic disease management in primary care patients with COPD is 
effective.27 Potential effects are further diminished by the low adherence of 
the participants to health behaviour recommendations, which is in 
concordance with other studies.25,28  
 
In conclusion, an ongoing respiratory expert-supported monitoring system 
for patients with COPD was not effective in terms of clinical outcomes. The 
lack of effectiveness may have been the result of a combination of limited 
options to intervene, the diluting effect on the intervention caused by the 
many steps in this complex process, and the low adherence of patients to 
crucial recommendations such as smoking cessation. 
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ll but one of the 18 selected clinical practice guidelines on the 
management of COPD recommend regular surveillance of the 
patient’s condition, or ‚monitoring‛ (Chapter 2). The most 
frequently recommended monitoring routine is to monitor lung function, 
especially of the FEV1, expressed as the percentage of the predicted value. 
Next, at least half of the clinical practice guidelines recommend monitoring 
symptoms, exercise tolerance, comorbidity, exacerbations, and smoking 
habits of COPD patients. In the Netherlands, primary care providers (i.e., 
GPs and nurse practitioners) provide care for the large majority of COPD 
patients. Most primary care COPD patients have only mild-to-moderate 
airflow obstruction and the coexistence of relevant prognostic monitoring 
factors (i.e., low BMI, high MMRC score, airflow obstruction) is low in this 
population (Chapter 3).  
 
The majority of COPD patients in primary care suffer from comorbid 
conditions (Chapter 4). Comorbidity can further deteriorate the physical 
condition of the COPD patient, which we found for obese COPD patients 
(BMI ≥ 30) who have lower FVC values and more symptoms compared 
with patients who have normal weight and are overweight (21 < BMI < 30) 
(Chapter 5). COPD patients also have a higher risk of a first diagnosis of 
depression compared with healthy individuals or diabetes patients (Chapter 
4). Regional diagnostic centres offer expert-supported COPD disease-
monitoring programs on a large scale to support primary care COPD 
management. However, despite their popularity with primary care 
providers and patients alike, in our study no evidence that such a system 
results in better long-term outcome of care was found (Chapter 6).  
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Scientific evidence for primary care COPD management 
The main dilemma in the management of COPD patients in primary care 
today is that most scientific evidence on how to diagnose and treat patients 
with COPD is based on studies of patients with advanced disease in 
secondary or tertiary care. Thus, primary care providers must rely on 
strategies that do not pertain to the vast majority of their patient population 
and should be used only in more severe cases.1 This confounds one of the 
basic principles of primary care: to specify interventions to the actual need 
of the individual patient and to protect patients from unnecessary 
procedures. 
 
To illustrate this: It is recommended that practitioners stage COPD based 
on a system that presents a composite picture of disease severity.2 
Multicomponent staging tools for COPD, like the BODE index (BMI, 
Obstruction, Dyspnoea, and Exercise tolerance) and CPI (COPD Prognostic 
Index), have recently been developed and are recommended for all patients 
with COPD.3,4 We examined the coexistence of three severity components 
(i.e., BMI, level of dyspnoea, and airflow obstruction) in a primary care 
COPD population (Chapter 3). In this population, the spectra of the severity 
components are strongly skewed toward mild outcomes, and the 
concurrent occurrence of these components was low. Thus, it is 
questionable if these staging tools will be able to discriminate disease 
severity levels in a primary care COPD patient population and, therefore, 
are applicable for primary care. 
 
Monitoring in general 
Monitoring has historically been an important component of good medical 
practice, because the periodic collection of information on the condition of 
a patient is essential to adjust and optimize treatment.   
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The number of monitoring routines in medical care has increased 
substantially, due to a number of trends: 1) increased screening 
opportunities and improved availability of sophisticated devices; 2) higher 
prevalence of chronic diseases, e.g., the proportional increase of the aging 
population; 3) increased awareness of monitoring options and assertiveness 
by patients; 4) recommendations by clinical practice guidelines; and 5) 
commercial interest (e.g., pharmaceutical industry that has a drug on the 
market that can manage the medical condition or companies that produce 
the monitoring devices).  
 
While monitoring can help establish better health awareness, stage disease, 
and guide treatment, unwarranted use of monitoring has several 
drawbacks: it can 1) be burdensome and risky for patients; 2) result in a 
false belief that change in unhealthy habits are unnecessary or that a visit to 
the doctor is not required; 3) cause anxiety or have legal consequences 
when information on diseases or risk factors become available; and 4) result 
in an unjustified increase in the use of health care resources. Thus, before 
considering monitoring the pros and cons should be carefully weighed 
against each other.  
 
Monitoring has been associated with both positive and negative results for 
a variety of chronic or recurrent diseases. B-type natriuretic peptide(BNP) 
monitoring in patients with heart failure resulted in a decrease of 
hospitalizations.5,6 Monitoring fractional exhaled nitric oxide (FeNO) levels 
in patients with asthma did result in patients’ decreased use of inhaled 
corticosteroids without comprising asthma control.7 In contrast, it was 
recommended to avoid the routine monitoring of bone mineral density in 
the first years after starting treatment with a potent bisphosphonate 
because it was found to be unnecessary and may even be misleading (i.e., 
the natural variation may mistakenly be considered as treatment benefits or 
failure by clinicians).8 
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Also, self-monitoring of blood glucose in patients with type II diabetes had 
no effect on blood sugar levels or the number of cases of hypoglycaemia 
after a year. Worse, anxiety and depression levels were higher in patients 
who monitored their blood glucose, against an extra cost of £100 million a 
year for Great Britain alone.9,10 
 
Monitoring of patients with COPD 
Lung function monitoring was the most frequently recommended routine 
by clinical practice guidelines (Chapter 2). Frequent lung function 
monitoring is an example of when the advantages of monitoring may not 
outweigh the disadvantages. Lung function decline is the key characteristic 
of COPD disease progression, but the progressive decline of lung function 
is resistant to treatment, other than smoking cessation.11 Confronting 
smokers with their airflow obstruction did result in a higher smoking 
cessation rate after one year, but this was not true for COPD patients.12,13 
Consequently, although primary care providers and patients may 
appreciate information on lung function, it would primarily serve 
informative purposes. Nevertheless, lung function testing is essential for 
the diagnosis of COPD and to stage its severity. Reassessment of the 
severity of airflow obstruction enables periodic restaging and stage-specific 
treatment. The ideal frequency of these restaging visits should be 
determined and most likely depends on disease severity, age, smoking 
status, and perhaps on other factors as well. The use of time, equipment, 
and facilities to evaluate the lung function in COPD patients may be more 
efficient when the decision on the frequency of lung function assessment is 
more tailored to the individual situation of the patient.  
 
Monitoring exercise tolerance, measured by the distance a patient can walk 
in six minutes (i.e., six-minute walking distance (6MWD) test), is also 
recommended by many guidelines. Before adopting monitoring exercise 
tolerance as recommended practice for primary care, the following 
questions need to be addressed: a) whether limited exercise tolerance is 
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present in primary care COPD patients; b) if present, whether it is 
prognostic for primary care COPD or worsening disease state; and c) if 
associated with COPD disease state and prognosis, whether exercise 
tolerance could be improved in the long run. Subsequently, it would be 
important to investigate alternative ways to determine the exercise 
tolerance, because limited space to set up a walking-circuit could restrict 
the 6MWD test routine in general practices.  
 
In contrast, monitoring health-related quality of life (HRQL) is only 
infrequently recommended by guidelines, despite its potential values 
(Chapter 2). HRQL brings together various aspects of an individual’s 
subjective experience that relate both directly and indirectly to health, 
disease, disability and impairment.14 Monitoring HRQL may facilitate a 
reciprocal caregiver-care recipient relationship that can improve patient 
satisfaction.15 Moreover, when disease management also serves the 
patients’ goals, this can increase the adherence to treatment and 
recommendations.16 There are several treatment options for COPD that can 
improve the HRQL of COPD patients, like self management,16 pulmonary 
rehabilitation,17 the use of an inhaled anticholinergic drug,18 and the use of 
a combination of an inhaled corticosteroid combined with long-acting b-
agonists.19,20 Again, most studies recruited patients with more severe 
disease stages, and the room for improvement in HRQL may be smaller in 
primary care COPD patients. In fact, the only study that evaluated the 
additional value of monitoring HRQL of patients with asthma and COPD 
in primary care suffered from a lack of room for improvement.21 The 
monitoring program was not found to be effective on clinical outcomes, but 
it did result in improved patient satisfaction. However, HRQL could be 
significantly impaired in COPD patients treated in primary care, as 
demonstrated in a cohort study.22 It is thus inconclusive that monitoring 
HRQL of patients with COPD may improve disease management and 
should be further evaluated.  
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Finally, at least half of the guidelines recommend monitoring respiratory 
symptoms, exacerbations, and smoking status. This information has the 
potential to guide currently available primary care COPD treatment. In 
other words, it provides insight into the disease state or progression that is 
responsive to change. But, because treatment options are limited and 
adherence to available therapy is currently low in COPD patients, the 
clinical results of these monitoring procedures may be limited.  
 
Comorbidity 
Real-world primary care patients cannot be pigeonholed in a medical 
condition of our expertise or interest. Comorbidity is a well-established 
phenomenon that we found in the majority of primary care COPD patients 
(i.e., coexistence of chronic conditions with a prevalence of more than 2% in 
the population) (Chapter 4). Patients with chronic airway obstruction are 
more likely to have medical conditions such as cardiovascular diseases, 
diabetes mellitus, osteoporosis, locomotive diseases, insomnia, sinusitis, 
migraine, depression, and cancer.23,24 From a patient’s point of view, the 
impact of the relative ‚mild‛ effects of COPD on their health status and 
daily life may not be a top priority. 
 
One illness that can have an overwhelming effect on patients is clinical 
depression.25 We found a statistically significant temporal relationship 
between COPD and depression, when controlled for other chronic 
conditions (Chapter 4).  
Depressed COPD patients have higher levels of activity reduction, 
disability, and work absenteeism compared with non-depressed COPD 
patients.26 Early recognition of depression in patients with COPD is 
therefore important, and information on determinants of patients at high 
risk for a depression could help physicians to identify depressed COPD 
patients. Some determinants that were found to be associated with higher 
scores on depression questionnaires were a) reduced HRQL, b) higher 
levels of airflow obstruction, c) living alone, d) increase of FEV1 after 
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bronchodilation, e) more respiratory symptoms, f) female gender, g) a BMI 
less than 25, and h) a higher level of physical impairment.27-29 The body of 
evidence supporting the connection between depression and COPD merits 
further assessment of effective ways to detect and treat depression in 
COPD patients. 
 
Contrary to our expectations, we could not establish a link between 
comorbidity and depression rates in COPD patients in the same population 
(Chapter 4).27 This is surprising, because multimorbidity has a major impact 
on the quality of life of patients with chronic airway obstruction.30 As we 
established a link between depression and COPD, this result warrants 
further investigation.  
  
We also studied the effect of comorbid obesity on lung function indices 
(FEV1 and FVC) and dyspnoea according to level of exertion (MRC-score) 
of primary care COPD patients. There is a focus on identifying 
underweight patients with COPD, but obesity is present in a relevant and 
much larger proportion of primary care COPD patients with potentially 
severe implications. Our key finding was that the FVC value was 
influenced by obesity, resulting in an underrepresentation of COPD in 
obese individuals when the main GOLD criterion (i.e., FEV1/FVC<0.70) was 
applied for airflow obstruction.  
 
While the above results appear to demonstrate that obesity has a negative 
effect on lung function capacity, other results have proven the opposite in 
specific cases. Obesity is associated with lower mortality rates of patients 
with severe COPD.31 As the paradoxical phenomenon implies, the 
relationship between obesity and obstructive lung disease is not fully 
understood. Systemic inflammation has increasingly been considered part 
of the non-pulmonary sequelae of COPD,32 and it has been found that 
obesity can increase systemic inflammation and its associated conditions 
(like ischemic heart disease, heart failure, osteoporosis, lung cancer, and 
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diabetes);33 the exact linkages between systemic inflammation, airway 
obstruction, and obesity have not been fully investigated.32 
 
The coexistence of multiple relevant chronic conditions presents a 
challenge to single disease-oriented disease management programs.34,35 For 
patients with complex and overlapping health problems, guidelines that 
focus on individual diseases may not apply. Obesity is a good example in 
this context: the recommended maximum weekly weight loss rate in 
guidelines on the treatment of obesity may not be appropriate or even 
harmful for COPD patients.36,37 The complicated interactions between 
disease manifestations and medical conditions deserve our attention. 
Moreover, Schünemann et al. recommend to use a grading system in 
guidelines that address whether or not the clinical evidence was based on a 
real-world COPD population or merely represent the effectiveness in a 
population with many exclusion criteria (like cormobid conditions).38 This 
could help clinicians to make an educated decision on the effectiveness of 
an intervention dealing with real-world COPD patients. 
 
Primary care may be the ideal setting to collect information on 
multimorbidity and coordinate treatment, because general practitioners 
have an overview of patients’ medical conditions. The use of an advanced 
electronic patient record could help the GP in fulfilling this challenging 
task. Though little is known about the management of patients with 
multiple conditions, a ‚guided care‛ program seems promising for elderly 
patients.39 A practice nurse and GP collaborate in this program, supported 
by an electronic patient record. The program comprises an assessment of 
the home situation of the patient, creating a care plan, promoting self-
management, monitoring patients’ conditions, coaching healthy behaviour, 
coordinating the patients’ transitions between sides and health care 
professionals, supporting the primary caregiver, and facilitating access to 
community resources. Compared with usual primary care in the United 
States of America, some positive effects on the quality of care were found 
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after six months, though the clinical effectiveness of the intervention (i.e., 
improved quality of life and cost-effectiveness) was not yet known.39,40 
 
Expert-supported monitoring system for patients with COPD 
The continuous monitoring by an expert support system did not result in 
clinical benefits for patients with COPD (Chapter 6). This principal finding 
of this dissertation is presumably the result of a combination of factors.  
 
As pointed out earlier, the treatment options for COPD are limited. In 
contrast to other chronic diseases, like diabetes mellitus and hypertension, 
there is no medication that influences the key feature of COPD; i.e., airflow 
obstruction. 
 
Currently, life style changes, particularly smoking cessation, are the key 
treatment options for COPD. This is even more true for mild-to-moderate 
COPD, as seen in primary care. We found that patients’ adherence to vital 
recommendations, such as quitting smoking, was low (Chapter 6). In fact, 
the evaluated program only intervenes indirectly on these key aspects of 
COPD management. Nonetheless, in general, COPD patients fail to make 
critical lifestyle changes with regard to smoking cessation, exercise, and 
diet.12,41 Therefore, the challenge for the next decade will be to develop and 
implement programs that will achieve life style changes. Increasing the 
success rate in implementing these changes might be one of the only 
effective ways to treat COPD.  
 
Another reason why the study did not find an association between 
monitoring and clinical results is the inherent limitation in an ‚expert 
system‛ whose recommendations are based on tested indicators, rather 
than the overall health status of the patient. In reality, the disease state of 
COPD is affected by a variety of conditions outside of test indicators, 
including: health expectations, comorbid conditions, and personal 
circumstances. The influence of COPD on daily life becomes more evident 
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only as the disease progresses. As a consequence, advice and 
recommendations from monitoring may have less relevance for the actual 
treatment of patients in an earlier disease state. For GPs, the outcome of the 
monitoring visits is just one of the many information sources for the 
management of their patients. 
 
Next, the expert-supported monitoring system is a complex intervention, 
involving multiple steps and decision-making on the part of the GP and 
patient. As shown in the process evaluation in Chapter 6, at each step the 
effect was diminished. One of the surprising observations was the 
inconsistency in the willingness of COPD patients to visit the regional 
diagnostic centre for monitoring and the unwillingness of patients to visit 
their GP’s office afterward to discuss the medical advice. It is possible that 
this disparity can be attributed at least partly to greater demands for 
monitoring visits at the regional diagnostic centre. Another possible 
explanation for this might be that COPD patients prefer the monitoring 
visits to doctor’s visits, because they like ‚knowing their number‛ or 
receiving attention. In contrast, the goal of the visit to the GP’s office is to 
discuss treatment, frequently involving life style changes that the patient is 
reluctant to undergo. From that perspective, it is not surprising that 
especially COPD patients who still smoke did not visit the GP’s office 
subsequent to the monitoring visit. Further research should be done to 
investigate the underlying motives of COPD patients to adhere to or defy 
recommended visits.  
 
Finally, it may be argued that we did not find effects in the study because 
we studied the effect of monitoring on a population with pre-existing entry 
into the monitoring system, rather than the effect of monitoring on a newly-
diagnosed population. The inclusion of a newly-diagnosed patient could 
have resulted in better clinical results. Our study produced results that 
mainly corroborate the findings of previous work in this field, which 
included patients with no previous monitoring history.42  
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Only the change in correct inhaler use differed significantly between 
monitored patients and the control group in this study.42 Our results 
indicate that keeping an expert-supported monitoring system in place for 
years, as is common practice, appears not to benefit COPD patients with 
mild-to-moderate disease severity.  
 
Recommendations for daily practice 
We caution against drawing the conclusion from this thesis that monitoring 
patients with COPD is not required. However, we found that ongoing 
monitoring by an expert support system did not result in clinical benefits 
for patients with COPD. Next, from the primary care point of view that 
patients should be protected from unnecessary procedures, frequent 
routine reassessment of pulmonary function should be reconsidered. The 
current COPD guideline from the Dutch College of General Practitioners 
was the first to question the usefulness of annual lung function assessment 
in non-smoking COPD patients with only mild disease. Primary care 
providers could benefit from information on the ideal lung function 
restaging frequency, based on characteristics like smoking status and 
current disease severity level. Guidelines could provide a framework of 
recommendations of lung function reassessment that can be utilized to 
decide whether or not to reassess the lung function of individual patients. 
However, clinical judgement should always play an important role in this 
decision. Especially because various aspects could influence the ideal 
frequency, the pros and cons of lung function assessment will be best 
balanced when an individual plan for patients is introduced (and adapted 
as situations change).  
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Spirometry by trained lung function technicians that use calibrated 
equipment and perform spirometry on a daily basis warrants the quality of 
test performance and is an important reason why monitoring visits were 
relocated to regional diagnostic centres. These benefits remain, and 
regional diagnostic centres could have a facilitating role for primary care 
COPD management by executing high-quality spirometric tests when 
requested by GPs. However, when lung function is no longer part of 
routine monitoring visits, monitoring could take place in the general 
practice, where COPD monitoring is handled primarily by practice nurses 
or GPs, supported as necessary by respiratory experts, continuing 
education, and diagnostic centres. Patients should be encouraged to 
comply with these visits, and GPs and practice nurses should focus on 
managing the overall health status with the consideration of the personal 
circumstances of the patient, relevant comorbid conditions, patient’s 
priority, and lifestyle factors. This would foster more individualised 
monitoring and health care plans for primary care COPD patients.   
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onitoring is the process of periodic collecting of information 
that guides disease management. The goals of COPD disease 
management are to delay the process of disease progression 
and alleviate its manifestations. The dissertation focuses on monitoring 
disease, treatment, and comorbidity of primary care COPD patients. 
 
In Chapter 1 the rationale behind monitoring COPD was discussed. 
Monitoring is an important instrument to adjust and optimise chronic 
disease management. Next, it could grade the severity of the disease and 
predict the prognosis. Since there are no treatment options to reduce the 
key characteristic of COPD disease progression - lung function decline - the 
primary achievable goal of COPD disease management is to alleviate the 
influence of the disease on the daily life of patients. In contrast to this focus 
of COPD disease management, lung function assessment has a central role 
in current COPD monitoring. Lung function testing is essential to diagnose 
COPD and stage its severity. As the disease progresses, periodic 
reassessment of the severity of airflow obstruction enables periodic 
restaging and the selection of concomitant stage-specific treatment. 
However, the added value of these lung function assessment at stated 
intervals seems low, especially in patients with mild-to-moderate COPD, 
which is the vast majority of the COPD population. It would make sense to 
recommend some monitoring procedures, especially the monitoring of 
symptoms and smoking status, as routine for every patient with COPD, 
and apply additional surveillance on the basis of disease severity stage. 
This would not only help to tailor care to the individual patients, but also 
prevent a lot of effort and resources being used for the routine collection of 
information that has no direct relevance to the management of the patient.  
 
Chapter 2 is a review of the current clinical practice guideline 
recommendations on monitoring routines for COPD. The follow-up of lung 
function indices was the most frequently recommended monitoring routine 
by the eighteen selected COPD guidelines. Moreover, monitoring of 
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symptoms, exercise tolerance, comorbidity, and smoking habits were 
recommended regularly. Only one guideline provided a different set of 
monitoring parameters for advanced COPD compared to mild and 
moderate COPD. None of the guideline recommendations was evidence-
based. Therefore, there is a major gap between the comprehensive clinical 
practice guideline recommendations on monitoring disease and the level of 
evidence to support these recommendations.  
 
Chapter 3 describes the (co-)existence of three ‚prognostic‛ staging factors 
in primary care COPD patients: level of airflow obstruction, level of 
dyspnoea, and body mass index (BMI). These factors were recommended 
by the ATS/ERS standards for the diagnosis and management of patients 
with COPD, but it is unclear whether prognostic levels are prevalent and 
coexisting in primary care COPD patients. In the large sample of primary 
care COPD patients (n = 2,023), some of the factors, especially a moderate 
airflow obstruction and moderate level of dyspnoea, were prevalent but 
only 3.4% of the population scored on all three factors. The low percentage 
of patients with coexisting prognostic factors in primary care warrants 
further investigation. Especially since there is increasing interest to 
introduce multidimensional instruments that includes these factors to 
assess COPD severity in primary care COPD management.  
 
Chapter 4 evaluate the temporal relation between COPD and depression. 
We compared the risk  for a physician diagnosed depression in patients 
with COPD, patients with diabetes mellitus (DM), and controls without 
chronic conditions based on the Continuous Morbidity Registration 
database. Cox’s proportional hazards analysis revealed that the risk of a 
first episode of depression in patients with COPD was higher compared to 
patients with DM as well as compared to matched controls without chronic 
conditions after correction for covariates. In other words, patients with 
COPD are more likely to be diagnosed with depression than patients with 
DM and controls without chronic conditions.  
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Chapter 5 describes the prevalence of obesity in primary care COPD 
patients as well as the association of obesity with worse disease state in 
primary care COPD patients. We found that obesity was slightly more 
prevalent in COPD patients (15.1%) than in the general Dutch population 
and resulted in higher level of dyspnoea according to the level of exertion. 
Especially the FVC value and not the FEV1 as percentage of predicted value 
of obese COPD patients was lower compared to COPD patients with 
normal weight and overweight. This is an important observation, as this 
could result in underrepresentation of COPD in obese individuals when the 
main GOLD criterion (i.e., FEV1/FVC<0.70) is applied to demonstrate 
airflow obstruction. Therefore, next to the general attention to underweight 
of patients with COPD also obesity deserves attention when diagnosing 
and managing COPD. 
 
In Chapter 6 the long-term effectiveness of a primary care monitoring 
system with respiratory expert recommendations for GPs’ management of 
patients with COPD compared to usual care is investigated. The 
intervention consisted of ongoing half-yearly monitoring of COPD patients 
with respiratory expert recommendations for the GP and was compared to 
usual care. The study was a multi-centre randomised clinical trial of COPD 
patients clustered by general practices. A detailed process evaluation was 
performed along with the trial. Half of the monitoring visits resulted in 
disease management recommendations by a respiratory expert and 45.6% 
of those recommendations were implemented by the GP. Adherence to 
lifestyle recommendations by patients was low. No important differences 
in two year change between the monitoring and usual care groups were 
found. Therefore, the ongoing respiratory expert supported monitoring 
system for patients with COPD was not clinical effective and could not be 
recommended. 
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The discussion part of this thesis debates the outcome of these studies and 
implications of the outcome for daily practice and further research. The 
main conclusions that can be drawn from this thesis are: 
 Current COPD monitoring is not evidence-based. 
 Lung function monitoring is the most recommended monitoring 
routine by COPD clinical practice guidelines followed by 
symptoms, exercise tolerance, comorbidity, and smoking habits. 
 The co-occurrence of three monitoring factors, recommended by the 
ATS/ERS to generate a composite picture of disease severity (i.e., 
BMI, dyspnoea, airflow obstruction), in a primary care COPD 
population was low.  
 Patients with COPD are at higher risk for a first episode of 
physician diagnosed depression than patients with diabetes and 
‚healthy‛ controls.  
 Obesity is prevalent in primary care COPD patients and results in 
higher levels of dyspnoea according to level of exertion and lower 
mean FVC value.  
 An ongoing respiratory expert supported monitoring system for 
patients with COPD was not clinical effective.  
 
From the primary care point of view that patients should be protected from 
unnecessary procedures, frequent routine reassessment of pulmonary 
function should be reconsidered. This does not imply that lung function 
testing is not essential for the diagnosis of COPD and to stage its severity. 
In fact, reassessment of the severity of airflow obstruction enables periodic 
restaging and should be considered. However, clinical judgement should 
play an important role in this decision. 
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Monitoring could take place in the general practice, where COPD 
monitoring is handled primarily by practice nurses or GPs, supported as 
necessary by respiratory experts, continuing education, and diagnostic 
centres. This would allow practice nurses and GPs to manage the overall 
health status with consideration of the personal circumstances of the 
patient, relevant comorbid conditions, patient’s priority, and life style 
factors. This would foster more individualised monitoring and health care 
plans for primary care COPD patients. 
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n dit proefschrift wordt geprobeerd om de vraag te beantwoorden of 
het zinvol is om COPD-patiënten te monitoren en of mensen met 
COPD een groter risico hebben op andere aandoeningen 
(comorbiditeit) en wat de consequenties daarvan zijn. In deze samenvatting 
wordt eerst basale achtergrondinformatie over COPD en monitoren 
gegeven, waarna de inhoud van het proefschrift besproken wordt.   
 
ACHTERGRONDINFORMATIE MONITOREN EN COPD 
Wat is monitoren? 
Monitoren is het periodiek verzamelen van informatie over de 
gezondheidstoestand van een persoon. Monitoren komt in het alledaagse 
leven veelvuldig voor. Het eens per week op een weegschaal gaan staan 
om het gewicht te bepalen is bijvoorbeeld een vorm van monitoren. Ook 
artsen monitoren de gezondheidstoestand van hun patiënten geregeld en 
dan met name van patiënten met een chronische aandoening. Zo wordt van 
diabetespatiënten periodiek de HBA1C bepaald en van patiënten met 
hypertensie de bloeddruk. Artsen gebruiken deze informatie om de 
behandeling te optimaliseren, zodat de klachten op korte termijn en de 
risico’s op lange termijn zoveel mogelijk beperkt blijven.   
 
COPD 
Een veelvoorkomende chronische aandoening is Chronic Obstructive 
Pulmonary Disease (COPD). Het is een verzameling van aandoeningen 
(zoals chronische bronchitis en longemfyseem) die met elkaar gemeen 
hebben dat de luchtwegen van patiënten vernauwd zijn. Dit wordt ook wel 
een luchtwegobstructie genoemd. Ondanks dat astma ook een chronische 
luchtwegaandoening is, zijn er diverse belangrijke verschillen met COPD 
en om die reden is de term CARA al jaren geleden in onbruik geraakt. Bij 
COPD is sprake van een permanent aanwezige luchtwegobstructie die 
grotendeels onomkeerbaar is en in de loop der tijd geleidelijk toeneemt. 
Het merendeel van de COPD-patiënten heeft een milde tot matig ernstige 
luchtwegobstructie en wordt daarvoor behandeld door de huisarts. Het 
I 
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roken van sigaretten is de belangrijkste, maar niet de enige, risicofactor 
voor het ontwikkelen van COPD. COPD leidt tot chronisch hoesten, 
slijmproductie en kortademigheid. Deze klachten kunnen toenemen door 
blootstelling aan prikkels zoals uitlaatgassen, sigarettenrook of parfum. 
Acuut optredende verslechteringen of opflakkeringen van COPD (ook wel 
exacerbaties genoemd) hebben een negatieve invloed op zowel de kwaliteit 
van leven van de patiënt als wel op de prognose. In Nederland lijden naar 
schatting zo’n 320.000 mensen aan COPD. Waarschijnlijk zijn dit er zelfs 
nog veel meer, omdat het hier enkel gaat om de mensen waarvan bekend is 
dat ze COPD hebben. COPD is daarnaast een belangrijke doodsoorzaak in 
Nederland.   
 
Risico op andere aandoeningen oftewel comorbiditeit 
Veel patiënten hebben naast COPD, andere (chronische) aandoeningen. In 
de medische wetenschap wordt het tegelijk hebben van meerdere 
aandoeningen comorbiditeit genoemd. Comorbiditeit kan ontstaan doordat 
aandoeningen dezelfde oorzaak hebben. Sigaretten roken is bijvoorbeeld 
ook een risicofactor voor het ontwikkelen van longkanker. Maar andere 
aandoeningen kunnen ook een gevolg van COPD of behandeling zijn. Zo 
kan COPD tot hartfalen leiden. Tot slot kunnen verschillende 
aandoeningen door toeval bij een persoon tegelijkertijd voorkomen. 
Comorbiditeit kan COPD verergeren en leiden tot meer 
ziekenhuisopnames en hogere zorgkosten. Het is daarom belangrijk te 
weten welke aandoeningen vaak voorkomen bij COPD-patiënten en wat de 
mogelijke consequenties daarvan zijn. Hierdoor kan comorbiditeit tijdig 
worden ontdekt en behandeld. In dit proefschrift is het voorkomen van 
twee belangrijke aandoeningen bij COPD-patiënten nader onderzocht, te 
weten obesitas en depressie.  
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Behandeling COPD 
COPD is niet te genezen. De behandeling van COPD richt zich met name 
op het stoppen met roken, omdat bij patiënten die blijven roken de ernst 
van de luchtwegobstructie alleen maar sneller toeneemt. Daarnaast kunnen 
benauwdheidklachten verlicht worden, onder andere door het gebruik van 
luchtwegverwijdende medicijnen. Ook het tijdig herkennen en behandelen 
van exacerbaties heeft een gunstig effect, bijvoorbeeld op de kwaliteit van 
leven van patiënten. Als de ernst van de ziekte toeneemt, dan richt de 
behandeling zich ook vaker op het verbeteren van de voedingstoestand en 
lichamelijke conditie (bijvoorbeeld in de vorm van longrevalidatie-
programma’s). Bij zeer ernstige vormen van COPD wordt soms chirurgisch 
ingegrepen of zuurstof toegediend. Bij het bepalen en/of handhaven van 
een optimale COPD behandeling kan monitoren een centrale rol innemen. 
Hiertoe dient de informatie die verzameld wordt wel aan te sluiten bij de 
behandelingsmogelijkheden.  
 
Een eerstelijns COPD monitoringsysteem 
Eerstelijns diagnostische centra ondersteunen huisartsen bij het 
diagnosticeren en monitoren van verschillende aandoeningen. Bij de 
Stichting Huisartsen Laboratorium (SHL) is een monitoringsdienst opgezet 
voor patiënten met astma en COPD. Eens per jaar worden deze patiënten 
opgeroepen voor een longfunctietest op een locatie van het diagnostisch 
centrum. Naast deze test wordt op gestructureerde wijze informatie 
verzameld over het rookgedrag, klachten, exacerbaties en medicatiegebruik 
in het afgelopen jaar. Longartsen en kaderhuisartsen astma/COPD 
beoordelen de uitkomsten van deze patiëntbezoeken en geven, indien van 
toepassing, schriftelijke adviezen aan de huisarts. De huisarts kan 
vervolgens samen met de patiënt tijdens een consult de uitkomsten 
bespreken en de behandeling aanpassen indien dat noodzakelijk blijkt te 
zijn. Inmiddels maken zo’n 7.000 patiënten gebruik van deze SHL 
monitoringsdienst.  
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Daarnaast vind een soortgelijke dienstverlening in grote delen van het land 
plaats. Het is echter nooit goed vastgesteld wat de gezondheidseffecten van 
een dergelijk service zijn.  
 
NEDERLANDSTALIGE SAMENVATTING PROEFSCHRIFT 
Hoofdstuk 1 betreft een redactioneel artikel waarin een mening wordt 
geven over het monitoren van COPD-patiënten. Op dit moment staat 
daarbij het bepalen van het longfunctieverlies (toename van de 
luchtwegobstructie) centraal. Ondanks dat longfunctieverlies het 
belangrijkste kenmerk is van een toenemende ernst van COPD, is deze 
informatie meestal niet nodig om de behandeling te optimaliseren. Immers, 
op dit moment is stoppen met roken de enige remedie om verder 
longfunctieverlies te beperken. Toch blijft het zinvol om zo nu en dan de 
longfunctie opnieuw te bepalen aangezien sommige behandelingen alleen 
effectief zijn voor patiënten met een ernstige luchtwegobstructie. Het 
monitoren van andere factoren, zoals klachten en exacerbaties, lijkt echter 
veel meer potentie te bezitten om de behandeling te optimaliseren. Om die 
reden wordt aanbevolen om verschillende monitoringfrequenties te 
hanteren voor de verschillende factoren, afhankelijk van de 
‚nieuwswaarde‛ van de verzamelde informatie. De ernst van de 
aandoening en aspecten zoals comorbiditeit zouden daarbij in overweging 
genomen moeten worden om een individueel monitoringsplan op te stellen 
en in de loop der tijd aan te passen.  
 
In hoofdstuk 2 worden de richtlijnadviezen met betrekking tot het 
monitoren van COPD-patiënten geïnventariseerd. Richtlijnen (protocollen) 
zijn documenten die als leidraad dienen voor artsen om een aandoening te 
diagnosticeren en te behandelen. Er zijn achttien COPD richtlijnen 
bestudeerd, en daarvan adviseerden er zeventien periodieke controles voor 
patiënten met COPD. Het monitoren van de longfunctie werd het meest 
frequent geadviseerd. Daarnaast adviseerden meer dan de helft van de 
richtlijnen om klachten, rookstatus, inspanningstolerantie en comorbiditeit 
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periodiek te vervolgen. Geen van de aanbevelingen, zowel met betrekking 
tot welke informatie verzameld zou moeten worden als hoe vaak dat zou 
moeten plaatsvinden, was gebaseerd op wetenschappelijke bewijs 
(evidence-based). Met andere woorden, alle adviezen zijn opgesteld op 
basis van ‚meningen van experts”. Omdat de invloed van monitoren op de 
behandeling en daarmee samenhangend de gezondheidstoestand van 
COPD-patiënten onbekend is, maar op grote schaal geadviseerd en 
toegepast wordt, is een wetenschappelijke onderbouwing van monitoren 
noodzakelijk.  
 
Sommige monitoringsfactoren, naast luchtwegobstructie, zouden 
informatie over de ernst van de aandoening en de daarmee 
samenhangende prognose verschaffen. Volgens de Internationale 
standaard voor de behandeling van COPD-patiënten, een gezamenlijk 
project van de Amerikaanse en Europese ‚respiratoire‛ genootschappen 
(ATS/ERS), geldt dit voor informatie over kortademigheid en de 
verhouding tussen lichaamslengte en -gewicht (body mass index oftewel 
BMI). In hoeverre bij eerstelijns COPD-patiënten ‚prognostisch relevante 
waarden‛ van deze factoren voorkomen, is beschreven in hoofdstuk 3. Het 
betreft hier een dwarsdoorsnede onderzoek van ruim tweeduizend 
eerstelijns COPD patiënten. De ‚prognostische‛ drempelwaardes zijn 
gesteld op een laag lichaamsgewicht (BMI < 21), een mate van 
kortademigheid waardoor mensen het minimaal niet volhouden om op 
vlak terrein samen met leeftijdsgenoten te wandelen of moeten stoppen om 
op adem te komen bij het wandelen in een normaal tempo (dit is MMRC-
score 2 of hoger), en de drempelwaarde voor luchtwegobstructie is gesteld 
op ten minste een FEV1 ≤ 64 procent van voorspeld.  
11,7% van de populatie had een lage BMI, terwijl een MMRC score ≥ 2 
voorkwam bij 28,7% van alle patiënten en er bij 53,9% van de populatie 
sprake was van tenminste een matige luchtwegobstructie. Daarentegen was 
het percentage patiënten wat aan meerdere criteria voldeed laag en slechts 
3,4 procent voldeed aan alle drie de criteria. Steeds vaker wordt 
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geadviseerd om de ernst van COPD vast te stellen op basis van scores die 
bestaan uit een samenstelling van de in deze studie gehanteerde criteria 
(bijvoorbeeld de BODE-index). Gezien de beperkte overlap tussen factoren, 
verdient de zinvolheid van deze aanbeveling voor eerstelijns COPD-zorg 
een grondige evaluatie. 
 
Het doel van hoofdstuk 4 was om te bepalen of COPD-patiënten een groter 
risico hebben om een depressie te ontwikkelen dan mensen zonder 
chronisch aandoeningen en diabetespatiënten. Daarvoor werden gegevens 
gebruikt van de Continue MorbiditeitsRegisratie (CMR), wat een cohort is 
met informatie over patiënten uit vier huisartspraktijken met een follow-up 
van ruim 35 jaar. Patiënten waarvan ten tijde van de diagnose COPD of 
diabetes nog nooit een depressie was vastgesteld werden ingesloten in de 
studie. ‚Gezonde‛ controledeelnemers bezaten op de dag dat ze in de 
studie gesloten werden geen chronische morbiditeit, die ten minste bij twee 
procent van de CMR-populatie voorkwam, en geen gediagnosticeerde 
depressie. De startdatum van deze individuen werd bepaald door ze te 
matchen aan COPD-patiënten die op basis van hun praktijk, geslacht, 
leeftijd en sociaal economische status hetzelfde risico hadden op een 
depressie (propensity score matching). Gebaseerd op Cox’s proportional 
hazard analyses bleek het risico (hazard ratio) voor een eerste episode van 
een gediagnosticeerde depressie 1,8 keer groter te zijn voor COPD-
patiënten ten opzichte van diabetespatiënten en 1,69 keer groter in 
vergelijking tot de ‚gezonde‛ controlegroep. Hieruit blijkt dat COPD-
patiënten dus een groter risico hebben op een gediagnosticeerde depressie 
dan diabetespatiënten en ‚gezonde‛ individuen. Een vroege erkenning en 
behandeling van een depressie kan de invloed hiervan op de 
gezondheidstoestand van de patiënt mogelijk beperken.  
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Hoofdstuk 5 beschrijft de prevalentie en de consequenties van obesitas 
voor patiënten met COPD. Van de 1.761 COPD patiënten uit een groot 
eerstelijns cohort was 15,1% obees (BMI ≥ 30). Ten opzichte van patiënten 
met een normaal gewicht of overgewicht (21 < BMI < 30) hadden obese 
COPD-patiënten vaker last van ernstigere kortademigheid bij inspanning 
(hogere MMRC-score). Daarnaast was met name de geforceerde vitale 
capaciteit (FVC) verlaagd en niet zozeer de FEV1. Met andere woorden, niet 
zozeer de hoeveelheid lucht die iemand in de eerste seconde geforceerd 
kan uitblazen, maar met name de totale hoeveelheid lucht die uitgeblazen 
wordt, blijkt beperkt te zijn. COPD wordt meestal gediagnosticeerd op 
basis van het criterium: FEV1/FVC. Als dus met name de FVC verlaagd is 
bij obese individuen dan kan dat tot onderdiagnostiek leiden. Vandaar dat 
het van belang is om rekening te houden met de invloed van obesitas op de 
uitkomst van longfunctieonderzoek en bij de behandeling van COPD.  
 
Hoofdstuk 6 betreft de evaluatie van de lange termijn effecten van een 
eerstelijns COPD monitoringsysteem in een tweejarig wetenschappelijk 
experiment waarbij huisartsenpraktijk gerandomiseerd werden (multilevel 
design). In deze studie werd in de interventiegroep het monitoringsysteem, 
wat beschreven is op pagina 145, geïntensiveerd naar halfjaarlijkse 
bezoeken terwijl in de andere groep de huisarts de patiënten zelf 
begeleidde zonder verdere inmenging (gebruikelijke zorg). De helft van de 
monitoringsbezoeken in de interventiegroep leidde tot aanbevelingen om 
het COPD-beleid aan te passen waarvan de behandelend huisarts 45,6% 
heeft geprobeerd te implementeren. Adviezen om de levensstijl te 
veranderen (zoals het stoppen met roken) werden door de COPD-patiënten 
slechts zelden opgevolgd. De verandering in kwaliteit van leven, klachten, 
longfunctie en aantal exacerbaties gedurende de studie verschilde niet 
tussen patiënten uit de interventiegroep en de patiënten die de 
gebruikelijke huisartsenzorg ontvingen. Geconcludeerd moet worden dat 
het continueren van een COPD monitoringsysteem op de lange termijn niet 
leidt tot gezondheidswinst van de patiënt. 
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In het discussiehoofdstuk van het proefschrift worden de resultaten 
bediscussieerd en samengevat. De belangrijkste bevindingen van dit 
proefschrift zijn: 
 Aanbevelingen in richtlijnen met betrekking tot het monitoren van 
COPD-patiënten zijn geen van allen gebaseerd op 
wetenschappelijke bewijs.  
 De meeste richtlijnen adviseren om de longfunctie periodiek te 
controleren en daarnaast beveelt meer dan de helft van de 
richtlijnen aan om ook de klachten, inspanningstolerantie, 
comorbiditeit en rookstatus te vervolgen.   
 Ondanks dat met name een matige kortademigheid en matige 
luchtwegobstructie geregeld voorkwamen bij eerstelijns COPD-
patiënten, kwamen deze factoren slechts zelden in combinatie voor.   
 Het risico op een gediagnosticeerde depressie was groter voor 
COPD-patiënten in vergelijking tot zowel diabetespatiënten als 
‚gezonde‛ personen.   
 Obesitas kwam bij een relevant percentage van de COPD-patiënten 
voor en is geassocieerd met een sterkere mate van kortademigheid 
en lagere FVC waarden.  
 Het geëvalueerde eerstelijns COPD monitoringsysteem was niet 
klinisch effectief op de lange termijn. 
 
Uit bovenstaande kan geconcludeerd worden dat COPD monitoring sterk 
gericht is op het vervolgen van de longfunctie. Op dit moment is de enige 
manier om longfunctieverlies te beperken het stoppen met roken. Om die 
reden heeft het periodiek verzamelen van gegevens over de 
luchtwegobstructie met name een informatief karakter en kunnen 
vraagtekens geplaatst worden bij het routinematig bepalen van de 
longfunctie. Longfunctieonderzoek blijft essentieel voor het diagnosticeren 
en herstadiëren van COPD. Na de diagnostische fase, zouden daarom 
longfunctietesten overwogen kunnen worden, rekening houdend met 
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patiëntgebonden factoren zoals de ernst van de aandoening, rookstatus en 
comorbiditeit.  
 
Indien de longfunctie niet standaard meer bij iedere periodieke controle 
bepaald wordt, dan wordt het eenvoudiger om monitorbezoeken in de 
huisartsenpraktijk te laten plaatsvinden. Een belangrijk voordeel hiervan is 
dat praktijkondersteuners en huisartsen meer informatie over de patiënt 
hebben, zoals informatie over comorbiditeit, leefomstandigheden en 
bereidheid om hun levensstijl te veranderen. De periodieke controles 
kunnen dan dus beter toegespitst worden op de individuele situatie van de 
patiënt. 
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et onderwerp van dit proefschrift is monitoren en er hebben dan 
ook heel wat monitoringsactiviteiten de afgelopen jaren 
plaatsgevonden. Dat geldt uiteraard voor de mensen met COPD 
en huisartsen die vrijwillig deelnamen aan de MONACO-studie, waarvoor 
mijn hartelijke dank. Maar daarnaast ben ik zelf onderwerp geweest van 
monitoringsactiviteiten van diverse pluimage. Al het monitoren heeft er toe 
geleid dat er nu een boekje ligt met slechts één naam op de voorkant maar 
ontelbaar veel mensen die een bijdrage hebben geleverd. Het zijn er zelfs 
zoveel dat ik nu al weet dat ik mensen ga vergeten. Mocht je dus niet 
genoemd worden…..weet dan dat dat expres is. Jouw bijdrage aan dit 
proefschrift was namelijk onbeschrijfelijk!  
 
MONITOREN VAN DE VOORTGANG VAN HET PROEFSCHRIFT 
Sneller dan het licht en altijd als eerste kwam de reactie van Chris van Weel 
(promotor) binnen, onafhankelijk van de tijdzone waarin hij zich op dat 
moment bevond. Dank je Chris voor je niet-aflatende snelle en inhoudelijk 
goede commentaren op alle manuscripten. Naast deze ‚klinische blik‛ 
zorgde Richard Grol (promotor) voor de noodzakelijke ‚kwaliteit van 
zorg‛ input. Het was uitdagend om beide visies samen te kneden tot een 
geheel maar juist deze combinatie van inzichten vond ik verfrissend. Jouw 
zitting in de promotiecommissie heeft tot de nodige verdieping gezorgd en 
op een aantal cruciale punten de doorslag gegeven. Tjard (Schermer, co-
promotor), na een turbulente leerzame Maastrichtse periode ben ik via jou 
in Nijmegen terechtgekomen. Je bent een zeer goede wetenschapper en ik 
ben dan ook erg blij dat ik de afgelopen jaren van je heb mogen leren. Ivo 
Smeele (co-promotor), ook wij kennen elkaar al wat langer dan dit project. 
Je hebt alle huisartsen persoonlijk benaderd om deel te nemen aan het 
project. Dat was een enorme klus, maar het resultaat was er dan ook naar. 
Jij was in het project met name degene die de praktische kant en 
consequenties in de gaten hield.  
 
H 
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Naast de promotiecommissie waren ook een aantal anderen betrokken bij 
de individuele hoofdstukken. Met name wil ik de stagiaires bedanken: 
Martijn Kolkman, Renate Smink en Joris Holkenborg (al heeft jouw werk, 
gezien de tijdsplanning, niet het proefschrift gehaald). Vaak met geringe 
onderzoekservaring hebben jullie fantastisch werk verzet. Hans en Reinier 
wil ik bedanken voor de broodnodige statistische ondersteuning. 
 
Niet alleen de inhoud, maar ook taalkundig en qua lay-out moest het 
proefschrift natuurlijk ‚ergens‛ over gaan. Twanny Jeijsman, die met haar 
deskundige blik mijn gepruts aan de lay-out heeft verbeterd, Monica, die 
de inleiding en discussie leesbaar gemaakt heeft en Esther Beekman die 
nog net voor haar vakantie de kaft ontworpen heeft.  
 
MONITOREN VAN HET ONDERZOEK 
De MONACO-studie was er een uit het boekje en dat is voor een heel 
belangrijk deel de verdienste van de Joke’s. Jullie zijn de stuwende kracht 
geweest achter deze studie. Dank voor het vele werk dat jullie verricht 
hebben en nog meer dank voor de gezellige thee-overleggen, de verhalen 
over de kroost en het behouden van humor, ook als het eens niet meezit 
(iemand zin in een chocolaatje?). 
 
Verder zijn er talloze (ex-)medewerkers van de SHL die een belangrijke 
bijdrage hebben geleverd aan de MONACO-studie, zoals Paulien van 
Hessen, Hilde, Maaike, afdeling ICT, Anja de Jongh, de medewerkers van 
het callcenter, de dames van de administratie, de longfunctiemedewerkers 
en astma/COPD consulenten. 
 
Ton van Boxem en Ivo, omdat zij het aangedurfd hebben om de door mij 
gebouwde beoordelingsmodule te gebruiken om daarmee alle longfuncties 
te beoordelen.  
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De voortgang van het project werd nauwkeurig gevolgd door Picasso. 
Terecht ook, want zonder de financiële steun van dit initiatief zou deze 
studie niet hebben kunnen plaatsvinden. Therese, Guus, Edmee, Xavier en 
het kernteam, bedankt! 
 
DE NOODZAKELIJKE RANDVOORWAARDEN  
Carla, Annelies, Jolette en Annet, dank dat ik als ‚gastarbeider‛ altijd bij 
jullie terecht kon, voor de gezellige tijd en de heerlijke cappuccino. 
Leandra, ik hoop dat er ook een boekje verschijnt met jouw naam op de 
kaft. Het was ontzettend fijn om op locatie een ‚soortgenoot‛ te treffen om 
zowel inhoudelijk mee te discussiëren als gezellig bij te kletsen.  
 
De Nijmeegse collega’s, met name de mensen van de CARA-groep, dank 
voor alle gezellige momenten. Maar ook Nathalie, voor de bemoedigende 
woorden op het moment dat ik er echt de brui aan wilde geven.   
 
Lotte en Caroline, we zitten ongeveer tegelijkertijd in hetzelfde schuitje. 
Jullie zijn echte duizendpoten en bewijzen wat mij betreft maar weer dat er 
ontzettend veel vrouwelijk talent rondloopt op onze afdeling en dat mee 
gaan lunchen absoluut niet de werkprestaties negatief beïnvloedt.  
 
Ook een aantal oud-collega’s wil ik graag bedanken, met name Sabine 
Kooijman. Samen hebben we van Pelikaan 1 een succes gemaakt ondanks 
een turbulente periode. Ondanks dat onze wegen zich professioneel 
gescheiden hebben, kan ik me niet voorstellen dat we elkaar privé uit het 
oog zullen verliezen. Karin Orbon, ooit mocht ik naast je staan toen jij je 
proefschrift verdedigde, een enorme eer. Je bent een ontzettend gezellige 
meid en ondanks het gewraakte hoofdstuk 4 zitten we hopelijk snel weer 
samen aan het bier. Margreet Jansen: niet een, maar twee keer zijn we al 
oud-collega’s van elkaar. Wie weet, drie keer is scheepsrecht. Mieke, wat 
ontzettend jammer dat je niet meer bij ons werkt.  
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DE PRIMAIRE UITKOMSTMAAT: KWALITEIT VAN LEVEN 
Uiteraard moest de kwaliteit van leven wel op peil blijven en ook daarin 
hebben een aantal mensen een rol gespeeld. Zo waren er de bijeenkomsten 
van ‚de meiden uit Nijmegen‛ (Binnenkort maar weer eens een 
appeltaartje eten met een enorme berg slagroom en een colaatje light), de 
wekelijkse repetitie van Siësta, Mariëlle; twintig jaar geleden werden we 
vrienden omdat we allebei ongestraft (qua studieresultaten dan) 
omgekeerd in het wiskundelokaal konden zitten in alles geïnteresseerd, 
behalve de wiskundeles. Tot de dag van vandaag kunnen we nog steeds 
urenlang kletsen over ‚de belangrijke dingen in het leven‛ zoals schoenen. 
Natuurlijk wil ik ook de bonte verzameling aan andere vrienden, (vage) 
kennissen en familieleden, die op een positieve manier voor de nodige 
afleiding gezorgd hebben en me geholpen hebben, bedanken!  
 
En dan mijn twee paranormaal begaafde bosnimfjes. Vinca, lang geleden 
was de afdeling huisartsgeneeskunde Maastricht onze enige gemene deler, 
maar dat is al lang verleden tijd. Je bent iemand die door dik en dun voor 
andere mensen gaat en als ik dan toch dat schavot op moet dan heb ik 
niemand liever naast me dan jij. Nicol, je hebt een geweldig gevoel voor 
humor en een heerlijke no-nonsense houding. Ich veul mich wie ein veske 
in ’t water met de meervoudig kampioen van het grootste muzikale 
evenement van Europa (de Moerebuuksj leedjesaovendj) naast me.  
 
Broertje, pijnlijk maar waar. Het is zo ver, dus ik hoop dat je al 
hartstochtelijk afscheid genomen hebt, want ik wil mijn contrabas terug! Ik 
hoor je toch nog steeds veel liever trompet spelen. Ik ben ontzettend trots 
op je. 
 
En dan mijn moedertje. Veel te jong moest je het zonder ‚ons pa‛ stellen en 
toch heb je altijd geprobeerd om voor mij geen weg onbegaanbaar te laten 
zijn. Dank voor je onvoorwaardelijke steun en voor wie je bent! 
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isette van den Bemt werd op 11 augustus 1972 geboren te Breda. Ze 
heeft van 1991 tot 1995 in Nijmegen de opleiding Voeding en 
Diëtetiek gevolgd. Vervolgens is ze gezondheidswetenschappen in 
Maastricht gaan studeren (studierichting BGK). Na in 1997 deze studie te 
hebben afgerond, heeft ze een tijd bij Beleid Economie en Organisatie van 
Zorg (BEOZ) van de Universiteit Maastricht gewerkt en als 
onderzoeksassistente bij het diagnostisch centrum van het Elkerliek 
Ziekenhuis. Vanaf 1999 was ze samen met Marjolein de Vries bij de 
vakgroep huisartsgeneeskunde van de Universiteit Maastricht 
verantwoordelijk voor het Ticaraproject (kan huisstofmijt-vermijding 
leiden tot verminderd gebruik van inhalatiecorticosteroïden van 
astmapatiënten) en later is ze ook betrokken geraakt bij de At RISK studie 
(vroege behandeling met inhalatiecorticosteroïden van kinderen die een 
groot risico hebben op het ontwikkelen van astma).  
 
Haar idee om een computerspel voor kinderen met astma te ontwikkelen 
om kwaliteit van leven in kaart te brengen is door ZonMW in 2003 
genomineerd voor de stimuleringsprijs. Inmiddels is dit computerspel 
ontwikkeld. Op dit moment wordt het instrument gevalideerd en de 
toegevoegde waarde van het toepassen van het computerspel in de 
dagelijkse zorg geïnventariseerd (het Pelikaanproject).  
 
Vanaf juli 2004 is ze als onderzoeker aan de afdeling Eerstelijns-
geneeskunde verbonden. Dit proefschrift (met name hoofdstuk 6) is het 
resultaat van de MONACO-studie (Monitoren van patiënten met astma en 
COPD in de eerstelijn) wat een samenwerkingsproject is met Stichting 
Huisartsen Laboratorium te Etten-Leur. Lisette woont in Breda en is nog 
steeds aan de afdeling Eerstelijnsgeneeskunde van het UMC St Radboud 
verbonden.  
L 
